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Giant cell arteritis (GCA), or temporal arteritis, is a large-vessel vasculitis affecting older 
41 people(1). Without high-dose glucocorticoid treatment, GCA can lead to occlusion of cranial 
42 
43 blood vessels, which may result in blindness or stroke(2). Most occurrences of blindness or 
44 stroke happen either before treatment, or during the first week of treatment(3). GCA is 
45 
46 therefore a medical emergency requiring immediate treatment. Many patients with GCA have 
47 inflammation of the aorta and its proximal branches (extracranial large-vessel involvement) 
49 which can lead to aortic aneurysm, dissection or rupture(4). Recent years have seen new 
50 
51 evidence emerge regarding diagnosis and treatment of GCA, requiring a major update of the 
52 2010 British Society for Rheumatology (BSR) guideline(5). 
53 
54 
Objectives To provide guidance for clinicians in the diagnosis and treatment of GCA, 
55 


















3 Target audience This guideline is intended for doctors and allied health professionals 
4 
5 who work in a primary or secondary care setting and manage patients with suspected 
6 and/or established GCA. 
8 
Areas not covered Takayasu arteritis(6), isolated polymyalgia rheumatica (PMR)(7, 8), and 
10 management of glucocorticoid-related complications such as osteoporosis(9). 
11 





17 This guideline was developed using GRADE (Grading of Recommendations, Assessment, 










28 “General Principles” are not necessarily evidence-based but are a description of generally- 
29 accepted best medical practice. Each General Principle carries a consensus score (mean rating 





36 How should suspected GCA be treated? 
37 
38 1. Patients in whom GCA is strongly suspected should be immediately treated 
39 
40 with high-dose glucocorticoids. Consensus score: 9.61 
41 
42 
“Strongly suspected” GCA means that in the assessing clinician’s judgement, GCA is a 
44 more likely explanation for the patient’s symptoms than any other condition. For doses, 
45 





How quickly should patients with suspected GCA be referred for evaluation? 
52 
53 2. GCA is a medical emergency. Each local healthcare organisation should have 
54 
55 information available to front-line clinicians, such as general practitioners and 
56 clinicians working in acute care, on how to refer patients with suspected GCA 
58 urgently for local specialist evaluation: patients should be evaluated by a 
59 














3 specialist ideally on the same working day if possible and in all cases within 3 
4 
5 working days. Consensus score: 9.17. 
6 
7 
GCA is a medical emergency and therefore “fast-track” referral pathways for urgent 
9 specialist evaluation of suspected GCA are beneficial. On suspicion of GCA, primary 
10 
11 care providers should initiate glucocorticoids alongside an urgent referral to the local 





17 To whom should patients with suspected GCA be referred? 
18 
19 
3. Patients with suspected GCA should be evaluated by a clinician with 
21 appropriate specialist expertise, usually a rheumatologist. Patients presenting 
22 
23 with a history of new visual loss (transient or permanent) or double vision 
24 
25 should be evaluated as soon as possible on the same calendar day by an 
26 ophthalmologist. Consensus score: 9.61. 
28 
29 What evaluations should be performed when starting treatment? 
30 
31 
4. When starting glucocorticoids for suspected GCA, diagnostically relevant 
33 symptoms and signs should be documented. Blood should be taken for full 
34 
35 blood count, C-reactive protein (CRP) and erythrocyte sedimentation rate 
36 (ESR) before or immediately after commencing high-dose glucocorticoids. If 
38 GCA is strongly suspected, the first dose of glucocorticoid can be given 
39 
40 without waiting for laboratory results. Consensus score: 9.61 
41 
42 
Diagnostically relevant symptoms and signs of GCA include headache; scalp hyperaesthesia; 
44 jaw or tongue claudication; temporal artery tenderness, nodularity or reduced pulsation; visual 
45 
46 manifestations including diplopia or changes to colour vision; limb claudication; polymyalgia 
47 rheumatica (pain and stiffness of shoulder and hip girdles); fevers, sweats or weight loss. Less 
48 
49 commonly, patients may have carotidynia, audiovestibular symptoms, dry cough, or 
50 indications of tongue or scalp ischaemia that may precede necrosis. However, as none of 
52 these symptoms are entirely specific for GCA, each is of limited use if taken in isolation(11) 
53 and differential diagnosis must also be considered. GCA causes elevation in platelet count, 
55 CRP and ESR. Plasma viscosity can be used where ESR is unavailable. These markers all fall 
56 
57 with glucocorticoid therapy; therefore, all patients should have blood drawn prior to starting 
58 treatment, unless there is evidence of critical ischaemia such as visual loss or diplopia and no 
59 
60 immediate access to phlebotomy. 
















6 What evaluations should be performed soon after starting treatment for GCA? 
7 
8 5. Patients treated for GCA should be evaluated for features of the disease 
9 
10 relevant to prognosis, such as clinical and laboratory features of a marked 
11 inflammatory response at diagnosis, ischaemic manifestations such as 
13 transient visual loss or jaw/tongue claudication, and signs or symptoms 
14 
15 indicating involvement of the aorta and its proximal branches; and for co- 
16 
17 morbidities relevant to treatment, such as diabetes mellitus, hypertension, and 
18 bone fracture risk. Consensus score: 9.53 
20 
21 Table 1 summarises recommended assessments for patients with GCA. As well as 
22 confirmatory tests for GCA (see Key Recommendation 1), alternative explanations for 







It is best practice for the prescriber of glucocorticoid therapy to ensure that patients are 
32 evaluated for hypertension and hyperglycaemia (blood glucose for acute changes and/or 
33 
34 HbA1c to identify patients that might be at greater risk) within the first 2 weeks of 
35 commencing high-dose glucocorticoids. Patients receiving high-dose glucocorticoids are 
36 






43 In GCA, involvement of the aorta and its proximal branches is often asymptomatic but 
44 
45 may cause vascular bruits or reduced blood pressure in one or both arms. Clinicians 
46 should be aware of an increased risk of thoracic aortic aneurysm and dilatation; this may 
47 
48 occur at any time during the disease course(4). However, routine aortic imaging for all 
49 GCA patients remains of uncertain cost-effectiveness. The optimal method and timing of 
51 imaging is still unclear(12). Therefore clinicians are advised to use their own discretion 
52 





Table 1. A proposed list of clinical assessments that could be carried out at or near diagnosis 
59 of giant cell arteritis (GCA). 

























































49 Legend for Table 1: 
50 
51 
52 *Screening tests for infection and osteoporosis to be considered in light of relevant local and 
53 national guidelines. Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation 
54 
55 rate; TSH, thyroid stimulating hormone; DXA, dual-energy x-ray absorptiometry.
History and examination Investigations 
 Height and weight 
 Features of GCA relevant to prognosis: 
fever, sweats, or weight loss; ischaemic 
manifestations (jaw claudication, 
tongue claudication) 
 Signs and symptoms indicating 
involvement of extracranial arteries 
e.g. bruits, different blood pressures in 
the two arms, limb claudication 
 Ophthalmological evaluation for 
patients with transient or permanent 
visual loss or diplopia 
 History of comorbidities and 
medications that might predispose to 
glucocorticoid-related adverse effects: 
infection, hypertension, diabetes, 
osteoporosis, low-trauma fracture, 
dyslipidaemia, peptic ulcer, psychiatric 
adverse effects 
 Features that may suggest alternative 
diagnosis, e.g. neurological deficits, 
very severe constitutional symptoms, 
or localised ear, nose and throat signs 
 Measures of activity of GCA: 
laboratory markers of inflammation 
(CRP for all patients, plus either 
ESR or plasma viscosity), and full 
blood count (platelet count may be 
elevated in GCA). 
 Consider serum protein 
electrophoresis and urine Bence- 
Jones protein/serum free light chains 
if ESR raised out of proportion to 
CRP 
 Baseline laboratory tests of major 
organ system function (plasma 
glucose, renal and liver function 
tests, calcium and alkaline 
phosphatase) 
 Screening tests for risk of serious 
infection* (may include urine 
dipstick, chest radiograph, tests for 
latent tuberculosis according to local 
or national protocol) 
 Screening tests for osteoporosis 
risk* (may include TSH, vitamin D, 
bone density test (DXA)) 
 











3 How should ongoing management of GCA be individualised? 
4 
5 
6 6. Full assessment of the disease and co-morbidities, and consideration of the 
7 patient’s personal priorities, should inform decisions about glucocorticoid 
9 tapering and initiation of additional treatments such as glucocorticoid-sparing 
10 
11 therapies. Involvement of, and clear communication with, primary care 
12 physicians is critical especially for management of multimorbidity. Consensus 
14 score: 9.67 
15 
16 
17 Table 2 shows an example of glucocorticoid tapering for GCA. 
18 





24 This is an example of glucocorticoid tapering based on that described in the 2010 BSR 
25 guidelines for GCA(5) and similar to the control arm of a recent clinical trial(13). High- 
26 
27 quality evidence comparing different glucocorticoid taper schedules in GCA is not available. 
28 Alternative approaches include, for example, reducing prednisolone by 10mg/week in patients 
29 
30 who are in remission above 20mg daily, and/or reducing the dose slower than stated here in 
31 patients who are on or below 5mg daily. In all cases taper schedules should be individualised 





























40-60mg oral prednisolone: initial dose for Continue at Purpose: 
patients with active GCA same dose until induction of 
 GCA clinical 
 symptoms and remission 
 acute phase  
 markers  
 resolve  
 
















































37 What education should patients be offered? 
38 
39 7. All patients with GCA should be provided with information about GCA and 
40 
41 its treatment. Patients should receive advice on diet, physical activity and 
42 stopping smoking. Consensus score: 9.47. 
44 
45 Information should be available at least in written format and ideally in multiple formats. 
46 Dietary considerations include mitigating the potential effects of glucocorticoid therapy on 
48 body weight, post-prandial glycaemia and bone fracture risk. Recommendations on physical 
49 
50 activity in inflammatory arthritis and osteoarthritis(14) may be tailored to individual patients 
51 with GCA. Patients should be signposted to relevant patient support groups or charities as 
52 
53 sources of peer support. Patients should be advised of potential symptoms of glucocorticoid 
54 withdrawal, although these are uncommon in practice. Patients should be advised about 
55 
56 alteration of glucocorticoid dose in intercurrent illness, especially including advice for 
7 seeking emergency attention if they suffer a vomiting illness necessitating parenteral 
59 glucocorticoid. 
In clinical remission, and above 20mg 
prednisolone 
Reduce daily 
dose by 10mg 


















In clinical remission, above 10mg prednisolone 
but less than 20mg 
Reduce daily 
dose by 2.5mg 
every 2-4 
weeks 
In clinical remission, and on 10mg prednisolone or 
less 
Reduce daily 



















6 What plans should be made for possible future GCA relapses? 
7 
8 8. During glucocorticoid taper and after glucocorticoid cessation, patients should 
9 
10 be informed what symptoms may suggest GCA relapse and what action the 
11 patient should take in these circumstances, including first point of contact for 
13 medical advice and how to contact the team providing specialist care. 
14 
15 Consensus score: 9.81 
16 
17 
Table 3 shows examples of symptoms that may signify relapse in patients with GCA, and 
19 how they might be managed. 
20 
21 
Table 3. Examples of symptoms that may signify relapse of GCA during 
23 glucocorticoid taper that require further evaluation and, if judged to be due to GCA 
24 
25 relapse, escalation of glucocorticoid treatment. 
26 
27 
This table outlines how new symptoms in GCA patients, in the absence of other risk 
29 factors or significant co-morbidities, may influence management decisions. New 
30 
31 visual loss or diplopia should be urgently evaluated by an ophthalmologist. Acute 
32 
33 phase markers should be measured and, if found to be elevated, may increase the 
34 clinical suspicion of GCA relapse. At present, the only agents with any evidence for 
























Symptom Possible significance in a 
patient with GCA 
Action to consider if 
symptom is judged to be 
due to GCA relapse 
Return of headache 
symptoms 
Possible GCA relapse 
without ischaemic 
manifestations 
Return to previous higher 
prednisolone dose 
Jaw or tongue 
claudication 
Possible GCA relapse 
with ischaemic 
manifestations 
Consider high-dose oral 
prednisolone (40-60mg) 





























19 Key recommendations 
20 
21 
22 The following evidence-based recommendations are graded as strong or conditional, with the 
23 quality of the evidence given as ++++ to + (unless no evidence was found) and a consensus 
24 
25 score to indicate mean strength of agreement. Further essential elaboration is added below 
26 where necessary. The underlying evidence and additional explanatory notes are presented in 
27 





33 Diagnostic tests for GCA 
34 
35 Which additional confirmatory diagnostic tests should be performed in all patients with 
36 
37 suspected GCA? (PICO 1, 2) 
38 
39 1. Strong recommendation: Patients with suspected GCA should have a confirmatory 
40 
41 diagnostic test. This could be either a temporal artery biopsy at least 1cm in 
42 
43 length, or an ultrasound of the temporal and axillary arteries, or both. QoE: +++ 
44 Consensus score: 9.33. 
46 
47 In selecting and interpreting the results of confirmatory diagnostic tests, pre-test probability 
48 (established on clinical grounds) should be taken into account(15) (Figure 1). A positive 
50 temporal artery biopsy, showing features of inflammation characteristic of GCA such as giant 
51 
52 cells or panarteritis(16), confirms the diagnosis of GCA. Isolated vasa vasorum vasculitis is 
53 not diagnostic of GCA. Due to the possibility of skip lesions, the length of biopsy should be 
54 
55 at least 1cm (post-fixation). Ultrasound is operator-dependent and requires adequate training, 
56 but has the advantage of access to both superficial temporal arteries in their entirety(15). 
57 
58 Where temporal artery histology findings are ambiguous (e.g. low-level inflammation 
59 restricted to the adventitia), discussion between the requesting clinician and the pathologist is 
Weight loss, fever, night Possible GCA-related Investigate with vascular 
sweats, anaemia, inflammation of the aorta imaging (MRI, CT or 
persistent acute phase and/or its proximal FDG-PET/CT); consider 
response, new/recurrent branches increasing oral 
PMR symptoms, limb  prednisolone and/or 
claudication, abdominal  adding glucocorticoid- 
pain or back pain  sparing agent 
 










3 desirable. In the absence of inflammatory infiltrate, a report of healed arteritis is not sufficient 
4 
5 to diagnose GCA. If neither vascular ultrasound nor biopsy is possible, and local MRI 
6 facilities and radiology support are available, then high-resolution 3 Tesla MRI of the cranial 
7 





13 Which tests can be used to evaluate involvement of the aorta and its proximal branches in 
14 GCA? (PICO 2, 3) 
15 
16 
17 2. Conditional recommendation: 18F-fluorodeoxyglucose positron emission 
18 tomography (FDG-PET), magnetic resonance angiography (MRA), computed 
20 tomography angiography (CTA) or axillary artery ultrasound may be used to 
21 
22 evaluate involvement of the aorta and its proximal branches. QoE: + Consensus 
23 
24 score: 9.36. 
25 
26 Since involvement of the aorta and its proximal branches in GCA may be asymptomatic or 
27 
28 associated only with constitutional symptoms, in some circumstances directed vascular 
29 imaging of the aorta and its proximal branches can be useful to detect inflammation, stenosis 
30 
31 or dilatation. FDG-PET can be useful for assessment of vascular inflammation although it 
32 provides less detailed anatomic definition of the involved arteries compared to MRA or CTA. 
34 Imaging may also be useful for follow-up assessments. Additional advantages of FDG-PET 
35 
36 and CT include potential value in the workup of alternative diagnoses such as malignancy and 
37 infection. Ultrasound can assess the axillary arteries but ultrasound evaluation of the deeper 
38 





44 Treatment of GCA 
45 
46 What is the best dose and route of initial glucocorticoid therapy for GCA in the absence of 
47 
48 ischaemic visual manifestations? (PICO 1-3) 
49 
50 3. Conditional recommendation: The standard initial glucocorticoid dose for GCA is 
51 
52 40-60mg oral prednis(ol)one per day. QoE: + Consensus score: 9.44. 
53 
54 
The vast majority of patients with GCA respond symptomatically within 1-7 days to a 40- 
55 
56 60mg daily dose of prednis(ol)one, apart from irreversible sequelae such as established visual 
57 loss, stroke or tissue necrosis. Failure to respond to this dose should prompt re-evaluation of 
59 the diagnosis. 













6 What is the best dose and route of initial glucocorticoid therapy for GCA in the presence of 
7 ischaemic visual manifestations? (PICO 4) 
8 
9 
10 4. Conditional recommendation: GCA patients with acute or intermittent visual loss 
11 
may initially be given 500mg – 1g intravenous methylprednisolone daily for up to 
13 3 consecutive days before commencing oral prednis(ol)one therapy. If 
14 
15 intravenous therapy is not immediately possible, this should not delay initiation of 
16 oral prednis(ol)one. QoE: + Consensus score: 9.00. 
18 
19 Acute visual loss due to ocular ischaemia in GCA requires immediate action. If intravenous 
20 
21 glucocorticoid therapy is not possible, 60-100mg oral prednisolone may be given for up to 3 
22 consecutive days. Clinical trials have not been conducted in patients with acute ocular 
23 
24 ischaemia, but observational data indicates that the vast majority of visual loss in GCA occurs 





30 How should glucocorticoid dose be tapered in GCA? (PICO 5) 
31 
32 
33 5. Conditional recommendation: Glucocorticoid dose should be tapered to zero over 12-18 
34 months, providing there is no return of GCA symptoms, signs or laboratory markers of 
36 inflammation. A more rapid dose reduction is appropriate for patients at high risk of 
37 
38 glucocorticoid toxicity and/or those receiving concomitant glucocorticoid-sparing 
39 therapy. QoE: + Consensus score: 8.81. 
40 
41 
42 All taper schedules assume close and regular clinical follow-up and good communication 
43 





What dosing frequency of oral glucocorticoid should be used in GCA? (PICO 6, 7) 
50 
51 6. Conditional recommendation: Patients should be prescribed a single daily dose of 
52 
53 glucocorticoid, rather than alternate day dosing or divided daily dosing. QoE: + 
54 Consensus score: 9.53. 
55 
56 
57 Should modified release prednisone be used in place of standard therapy? (PICO 8) 
















3 7. No recommendation can be made for the use of modified release prednisone in the 
4 
5 treatment of GCA. QoE: insufficient evidence. Consensus score: 9.72. 
6 
7 
When should further, non-biologic immunosuppression be added to glucocorticoid therapy 
9 for GCA? (PICO 9,10) 
10 
11 
8. Conditional recommendation: Methotrexate might be considered for GCA, in 
13 combination with a glucocorticoid taper, in patients at high risk of glucocorticoid 
14 
15 toxicity or who relapse. There is insufficient evidence to recommend any other 
16 
17 oral immunosuppressive agent in GCA, including azathioprine, leflunomide or 
18 mycophenolate mofetil. QoE: ++ Consensus score: 8.92. 
20 
21 Methotrexate, which may be given orally or by subcutaneous injection, has been used at doses 
22 of 7.5-15mg weekly in clinical studies and up to 25mg weekly in clinical practice. On the 
24 basis of three randomised controlled trials, conducted in patients with recent-onset GCA, the 
25 
26 evidence for methotrexate as a glucocorticoid-sparing agent in GCA remains equivocal, 
27 acknowledging limitations of the evidence base. In contrast, other immunosuppressants 
28 
29 (including azathioprine, leflunomide, mycophenolate) have not been adequately tested in 
30 clinical trials. The potential toxicity of dapsone or ciclosporin is likely to outweigh any 





37 Which biologic agents can be used for GCA in addition to standard therapy? (PICO 11, 12) 
38 
39 
9. Strong recommendation: Tocilizumab can be considered for GCA, in combination with a 
41 glucocorticoid taper, especially in patients at high risk of glucocorticoid toxicity or who 
42 
43 relapse. TNF inhibitors are not recommended in GCA. QoE: +++ Consensus score: 9.61. 
44 
45 
Tocilizumab was approved for GCA by the US and European regulatory authorities in 2017 
47 on the basis of two randomised clinical trials (13, 17) of one year of tocilizumab versus 
48 
49 placebo, alongside tapering oral glucocorticoid therapy, demonstrating efficacy for 





55 Although efficacy was demonstrated both in new-onset and relapsing GCA, the cost- 
56 
57 effectiveness of a glucocorticoid-sparing therapy in GCA is likely to be better in those with 
58 relapsing GCA, or in those GCA patients for whom the dose required to control disease 
59 
60 activity exceeds the maximum glucocorticoid dose acceptable for that individual, for example 








3 due to co-morbidities such as neuropsychiatric glucocorticoid-related adverse effects, 
4 





10 UK prescribers should be aware that at the time of writing a limited duration of tocilizumab 
11 therapy for GCA has been approved by the Scottish Medicines Consortium and by NHS 
12 
13 England for defined patient groups, taking into account cost-effectiveness data available at 





19 Clinical trials of TNF inhibitors have failed to demonstrate efficacy in GCA. One small trial 
20 
21 of abatacept for GCA has been reported(18), but so far there is insufficient evidence to make 





27 Should anticoagulant or antiplatelet agents be given for GCA? (PICO 12-15) 
28 
29 
30 10. The routine use of antiplatelet or anticoagulant agents for GCA is not 






There is a lack of evidence for the use of antiplatelet or anticoagulant agents 
38 specifically for GCA. National and society guidelines for the secondary prevention of 
39 





45 Should cholesterol-lowering agents be given for GCA? (PICO 16) 
46 
47 11. The routine use of cholesterol-lowering agents such as statins for GCA is not 
48 
49 recommended. QoE: insufficient evidence. Consensus score: 9.53 
50 
51 
There is a lack of evidence for the use of cholesterol-lowering agents specifically for GCA. 
53 National and society guidelines for the secondary prevention of coronary and other 
54 
55 atherosclerotic vascular diseases should be followed. 
56 
57 













3 Figure 1. A possible approach to using rapid-access vascular ultrasound to assist in clinical 
4 



































This figure illustrates a possible approach to using rapid-access vascular ultrasound, if 
41 available, in suspected GCA. Estimation of probability of GCA is based on all information 
42 
43 available (symptoms, signs, laboratory tests, and alternative non-GCA explanations for the 
44 clinical picture) and can be updated based on new information (clinical course, result of 
45 
46 temporal and axillary ultrasound and/or result of temporal artery biopsy). This assessment is 
47 based on clinical judgement and should ideally be performed by an individual with specialist 
48 
49 expertise. Note that for a medium (20-50%) estimated probability of GCA, it may be useful to 
50 perform an ultrasound prior to biopsy, in case the biopsy is negative. For a high clinical 
52 probability of GCA, a positive ultrasound alone may be sufficient, as illustrated here; 
53 
54 however, in these cases it is still acceptable to perform biopsy in addition to ultrasound in 
55 order to further increase diagnostic certainty. In the absence of clinical features of cranial 
56 
57 GCA, temporal artery biopsy can still be positive, but imaging of the extracranial large 
58 vessels may be considered instead of, or in addition to, temporal artery biopsy. Recently 
60 various clinical prediction rules have been proposed to assist clinicians in the estimation of 
Continue to 







Biopsy positive Biopsy negative 









High (>50%) Medium 
(20-50%), 





Estimate probability of GCA from symptoms, signs and 
laboratory tests 











3 probability of GCA; the performance of a clinical prediction rule developed in another setting 
4 
5 should ideally be checked using local audit data prior to adopting into local clinical practice. 
6 If rapid-access vascular ultrasound is not available, patients treated for suspected GCA should 
7 
8 all have a temporal artery biopsy. None of these tests should delay the prescribing of high- 
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45 1. Background to disease 
46 
47 
48 GCA is a large-vessel vasculitis affecting older people, with highest incidence among persons 
49 
50 70-79 years of age(1). Due to forecasted demographic changes, it has been estimated that 
51 
52 between 2014 and 2050, more than 3 million people will have been diagnosed with GCA in 
53 




In GCA there is inflammation within the walls of medium and large-sized arteries, with 
59 associated intimal hyperplasia(3). The ischemia to end organs results in characteristic 
60 











3 clinical features such as jaw or limb claudication(4). Visual loss or stroke may occur in GCA, 
4 
5 attributed to vascular occlusion; most GCA-associated visual loss occurs prior to 
6 
7 glucocorticoid treatment or shortly after treatment initiation, underlining the importance of 
8 
9 immediate treatment if the disease is strongly suspected(5, 6). The reported proportion of 
10 
11 patients with visual loss in GCA varies depending on the GCA case-finding method and 
12 method of ascertainment of visual loss; for example, in a UK study recruiting from a 
14 rheumatology setting, 17% of 271 patients with GCA reported irreversible visual loss, and 
15 
16 1% had stroke(7). Headache, scalp tenderness, jaw claudication, visual loss and stroke are all 
17 
18 classified as cranial manifestations of GCA(4). In addition, inflammation of the aorta and/or 
19 
20 its proximal branches is common in GCA; this is often called large-vessel vasculitis outside 
21 
22 the head and neck (LV-GCA), and may be asymptomatic or produce non-specific systemic 
23 symptoms, such as fever or weight loss. Vascular imaging in GCA demonstrates large-vessel 
25 involvement, usually with some degree of aortitis, in up to 83% of cases(8). This large-vessel 
26 
27 inflammation may lead to later development of vascular stenosis, aneurysm or dilatation, 
28 
29 dissection or rupture (9). A subset of patients with LV-GCA presents with symptoms of a 
30 
31 systemic inflammatory syndrome, which can have features of polymyalgia rheumatica 
32 
33 (PMR) without the classical cranial clinical features of GCA(4). The true prevalence of this is 








43 As GCA is considered a medical emergency, it is treated at the point of diagnosis by 
44 clinicians in primary and secondary care who have a wide variety of clinical backgrounds. It 
46 is therefore necessary to provide clear guidance about current best practice, and the 
47 




52 Recent years have seen new evidence emerge regarding diagnosis and treatment of GCA. 
53 
54 For this reason, major revision to the 2010 BSR Guidelines for the management of GCA (10) 
55 was required. We also broadened the remit of the previous guideline to include diagnostic 

















7 To provide guidance for clinicians in the diagnosis and treatment of GCA. This guideline is 
8 
9 supported by evidence wherever some evidence exists, and by expert consensus where 
10 
11 current evidence alone cannot provide a definite answer. The patient population covered by 
12 this guideline includes those patients in whom GCA is suspected sufficiently strongly that a 
14 decision to initiate glucocorticoid treatment is made. These guidelines are not limited to 
15 
16 GCA related temporal (cranial) arteritis but include also patients presenting with LV-GCA 
17 




22 The evidence search was restricted to adult humans with GCA or suspected GCA, not limited 
23 
24 by ethnicity, age or sex; however, as GCA is extremely rare in patients under 50 years(1), 
25 










36 Takayasu arteritis and other forms of vasculitis (e.g. secondary large-vessel vasculitis) are 
37 not covered by this guideline. The treatment of uncomplicated PMR is outside the scope of 
39 this guideline; readers are referred to the most recent BSR and ACR/EULAR guidance on 
40 
41 management of PMR(11, 12). Guidance regarding immunisations and prophylaxis of 
42 









This guideline is intended for doctors and allied health professionals who work in a primary 
53 or secondary care setting and manage patients with suspected and/or established GCA. 
54 
55 From a diagnostic perspective, early recognition of suspected GCA by the non-specialist is 
56 
57 encouraged, but definitive diagnosis of GCA can be challenging and therefore prompt 
58 
59 onward referral to an appropriate specialist is recommended. From a treatment 
60 






3 perspective, this guideline is intended to provide a framework by which specialists, general 
4 
5 practitioners and patients can work together to deliver optimal care tailored to the 
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3 Stakeholder involvement 
5 
6 
7 The guideline was developed in accordance with the BSR Guidelines Protocol. 
8 
9 Members of the Working Group co-authored this guideline and are listed at the end of this 
10 
11 document with their affiliations. Important stakeholder representation included patient 
12 
13 groups (PMRGCAuk, PMR and GCA North East, PMR-GCA Scotland) and the Royal College of 
14 Ophthalmology. Individuals on the Working Group had a range of expertise including 
16 rheumatology, general practice, ophthalmology, specialist rheumatology nursing, and 
17 
18 systematic review and guideline development methodology, and included patients with 
19 
20 personal experience of GCA. There was no representation from industry. Informal feedback 
21 
22 was sought at open meetings held at several international rheumatology conferences to 
23 
24 ensure that the guideline development process took account of current practice and 
25 important clinical questions within the wider rheumatology community, particularly 
27 regarding general principles of management. 
28 
29 
30 Prior to defining the Population-Intervention-Comparator-Outcome (PICO) questions, 
31 stakeholders were consulted regarding outcomes of importance in GCA(15). 
33 
34 A list of candidate outcomes was identified after feedback from all the stakeholders and 
35 
36 from a scoping literature review. A survey was undertaken to prioritise candidate 
37 outcomes. A total of 67 patients, 45 rheumatologists, 10 generalists (general practitioners 
39 or hospital based) and 7 ophthalmologists responded to the questionnaire. Each outcome 
40 
41 was graded based on its relative importance for clinical decision-making on a 1 to 9 point 
42 
43 scale(15). Scores from 1-3 indicated limited importance (not important for decision making), 
44 
45 4-6 important (important, but not critical for decision making) and 7-9 critical (critical for 
46 
47 decision making). Outcomes deemed as critical (i.e. score ≥7) by at least 70% of physicians 
48 and/or patients were considered as candidate outcome measures and this list was refined 
50 by the Guideline Working Group for the purpose of defining a list of “outcomes” for the 
51 






















3 The GCA Guideline Working Group developed the PICO questions, discussed the evidence 
4 





10 Rigour of Development 
11 
12 


























39 2. For recommendations on treatment, the (P) target population comprises patients 
40 with a diagnosis of GCA/patients with a high suspicion of GCA above the treatment 
42 threshold, (I) intervention and (C) comparator are the alternative management 
43 
44 strategies, (O) outcomes listed below(16). 
45 
46 3. For prognostic factors, the (P) target population comprises patients with a diagnosis 
48 of GCA, (I) the presence and (C) the absence of a prognostic factor, (O) outcomes 
49 
50 listed below(17). 
51 
52 A preliminary list of PICO questions was identified by a face-to-face discussion at the first 
54 guideline development group meeting followed by an e-mail based survey of the Working 
55 
56 Group. These preliminary questions were refined and grouped together where appropriate 
57 
58 at the second guideline development group meeting. This resulted in a final list of PICO 
59 
60 questions (Appendix C). 
The systematic literature search was directed according to pre-defined questions in PICO 
(Population, Intervention, Comparator, Outcome). These were written by the Working 
Group and feedback was explicitly invited from the patients within the group. The PICO 
questions were structured as follows: 
1. For recommendations on diagnostic imaging tests, the (P) target population 
interest, the (C) comparator is the comparator test or the reference standard, and 
the (O) outcomes are true positives, true negatives, false positives, false negatives, 
complications related to test, resource use, inconclusive results and the implication 
of these items on patient-important outcomes as listed below(16). 










3 The PICO questions were used to formulate a protocol for the systematic review, which was 
4 
5 approved by BSR before commencing searches. Screening of the search output was 
6 
7 performed by two group members for each topic (diagnostic tests: C. Duftner, S. 
8 
9 Appenzeller; therapeutic strategies: C. Dejaco, D. Camellino; prognostic factors: S. Gonzalez- 
10 
11 Chiappe, A.W. de Souza) who independently selected full texts, extracted data and 
12 performed quality appraisal. Any disagreements between these two group members were 
14 resolved by discussion, consulting a third member (S. Mackie, A. Hutchings or A. Mahr, 
15 
16 respectively) where no consensus could be reached. The literature search was last updated 
17 
18 on 18th June 2018 by G. Reynolds and the outputs appraised by the same group members as 
19 
20 before for consistency. 
21 
22 The search strategy of electronic databases is given in Appendix D. Further published studies 
23 
24 were identified by hand-searching the reference list of full and review articles and by 
25 
26 contacting experts in the field. In addition to this, ClinicalTrials.gov, ISRCTN and EU Clinical 
27 
28 Trials Register were searched, and the literature tracked to identify published trial results. 
29 
30 Criteria for selecting articles for full-text review are given below. 
31 
32 Diagnostic studies: We included full research articles of prospective studies involving >20 
33 
34 patients and investigating the index test in patients with suspected GCA. We did not 
35 
36 evaluate temporal artery biopsy as an index test because of incorporation bias in relation to 
37 
38 the reference standard. We excluded diagnostic case-control studies because this type of 
39 
40 study design produces estimates of diagnostic accuracy that are not applicable to routine 
41 clinical practice(18); studies where the index (imaging) test had been performed in >10% of 
43 patients upon treatment with glucocorticoids for >1 week (because imaging tests for GCA 
44 
45 suffer significant loss of sensitivity after commencing high-dose glucocorticoids; having an 
46 
47 imaging test within 1 week of initiating glucocorticoids appears feasible in practice(19)); 
48 
49 studies with a reference standard other than clinical diagnosis (without formal criteria), ACR 
50 
51 classification criteria and/or temporal artery biopsy result; and studies that could not be 
52 assigned to any of the PICO questions. 
54 
55 Interventional studies: We included randomized controlled trials involving >20 patients 
56 
57 with GCA. Observational or non-randomised studies, or studies that could not be assigned 
58 to any of the interventional PICO questions, were excluded. 
60 











3 Prognostic studies: We included prospective and retrospective studies on >100 GCA 
4 
5 patients investigating primarily the relevance of any of the prognostic factors of interest. 
6 
7 Studies with another research focus (e.g. description of a cohort, interventional trials) were 
8 
9 excluded for this part of the SLR. We further excluded studies that did not report the result 
10 
11 of a statistical test for association with the outcome. The prognostic factors being 
12 investigated should have been in routine clinical use without requiring sophisticated 
14 equipment or complex analysis. A minimum time for follow-up in eligible studies was set at 
15 
16 6 months. Because the aim of this part of the SLR was to identify factors that could be used 
17 
18 to risk-stratify patients in routine clinical practice, studies that reported exclusively on 
19 







27 Study details and results were extracted using a data extraction form from included articles 
28 
29 by two members of the literature review team according to GRADE methodology(20). The 
30 preliminary data extraction form was piloted in 5 identified articles and evaluated for 
32 completeness and handling. This data extraction form included the following items: 
33 
34 authorship and publication, design, main study population, primary study objective(s), 
35 
36 links/overlap with other studies, study inclusion criteria, characteristics of participants, 
37 
38 definition of intervention/exposure and control, definition of outcome, method of statistical 
39 
40 analysis, length of follow-up, losses to follow-up, missing data, discrete/continuous data 
41 (counts, means, standard deviations etc.), measures of effect and uncertainty, and any 
43 other information relevant to quality assessment. Additional parameters extracted relevant 
44 
45 to diagnostic studies included use of glucocorticoids before performance of imaging, disease 
46 
47 characteristics (number (%) of patients fulfilling clinical criteria for GCA, number (%) of 
48 
49 patients with positive temporal artery biopsy, number (%) of patients with large-vessel 
50 
51 GCA), technical aspects (imaging devices used, elementary lesions and structures 
52 investigated, blinding of the index test to reference standard), index test, reference 
54 standard, diagnostic performance (raw data to calculate sensitivity, specificity, positive (LR+) 
55 
56 and negative likelihood ratio (LR-)) and parameters required for assessment of study quality 
57 
58 (risk of bias). Additional data extracted relevant to prognostic factors included adjusted and 
59 
60 



















10 Quality assessment 
11 
12 
We evaluated the quality of evidence using the approach set out by GRADE(20, 21), 
14 implemented as follows: 
15 
16 
17 1.   Risk of bias: Confidence in the estimate of the effect decreases if studies have major 
18 limitations that may bias their results. For diagnostic studies, risk of bias was 
20 assessed using the QUADAS-2 tool(22) . For interventional studies, the following 
21 
22 factors were considered(20): randomisation procedure and sequence generation; 
23 
24 allocation concealment; blinding of patients and assessor; completeness of outcome 
25 
26 reporting (attrition bias: losses of follow-up, adherence to the intention to treat 
27 
28 analysis or stopping the trial early for benefit); selective outcome reporting. For 
29 prognostic studies, risk of bias was investigated using the following questions(17): 
31 
32 1. Was there a representative and well-defined sample of patients? Was selection 
33 
34 bias avoided? 
35 
36 2. Was follow-up sufficiently long and complete? 
37 
38 3. Were objective and unbiased outcome criteria used? Were methods used to 
39 
40 determine/measure outcomes adequate? 
41 




47 5. Was there adjustment for important prognostic factors, including age, sex, ESR, 
48 ischemic manifestations (amaurosis fugax, jaw claudication, limb claudication) 
50 extracranial manifestations, symptom duration, comorbidities, constitutional 
51 
52 symptoms, smoking? 
53 
54 2. Inconsistency of results: Confidence of the estimate of the effect decreases if there is 
56 variability in results (heterogeneity) across studies and investigators fail to identify a 
57 
58 plausible explanation. 
59 
60 









3 3. Indirectness of the evidence: Confidence of the estimate of the effect decreases if 
4 
5 there are differences between the population, intervention, comparator or outcome 
6 
7 of interest, and those included in the systematic review studies. 
8 
9 4. Imprecision: Confidence of the estimate of the effect decreases if the systematic 
10 
11 review includes relatively few patients and few events and thus has wide confidence 
12 
13 intervals and/or the extremes of the confidence intervals are close to the null effect. 
14 
15 5. Publication bias: Confidence of the estimate of the effect decreases if there is 
16 
17 evidence that some studies were not reported. 
18 
19 
Evidence generated from prospective diagnostic accuracy studies, randomized controlled 
21 trials and longitudinal cohort studies investigating prognostic factors started as high quality 
22 
23 but was downgraded if any of the above limitations was present. 
24 
25 
After assessing these five domains the overall QoE was assessed as: 
27 
28 1. High quality evidence (indicated by ++++ (A) – further research is very unlikely to 
29 
30 change our confidence in the estimate of effect) 
31 
32 2. Moderate quality (indicated by +++ (B) – further research is likely to have an 
33 




38 3. Low quality (indicated by ++ (C) – further research is very likely to have an important 
39 









49 Preparing the evidence report 
50 
51 Evidence tables were prepared by the literature review team for each PICO question using 
52 
53 Review Manager (RevMan) and GRADE profiler (GRADEpro) software. 
54 
55 The evidence profiles contained the following specific information: 
56 
57 Diagnostic studies: Direct outcomes (true positives, true negatives, false positives, false 
59 negatives, sensitivities and specificities; complications of the index test and of the reference 
60 












3 standard; resource use), the number of studies and quality assessment related to each of 
4 
5 these outcomes and the effect estimate (i.e. number of individuals classified per 1000 
6 
7 people) according to different pre-test probabilities (low (<20%), intermediate (20-50%) and 
8 
9 high (>50%) pre-test probability). 
10 
11 Interventional studies: Benefits and harms for each outcome across studies, the assumed 
12 
13 and corresponding risk for comparators and interventions (95% confidence interval (95% 
14 
15 CI)), the absolute and relative effect (95% CI), the number of participants / number of 
16 
17 studies, and number needed to treat, and the QoE including quality factors for each critical 
18 and important outcome. 
20 
21 Prognostic studies: Odds ratios, relative risks or hazard ratios were extracted as well as 
22 
23 corresponding p-values, both unadjusted and (where available) adjusted for confounders. 
24 Results of quality appraisal were also reported. 
26 
27 Whenever possible, meta-analyses using fixed effect methods (interventional studies) or 
28 
29 random-effect methods (diagnostic, prognostic studies) were conducted to combine the 
30 results of studies for each PICO question. 
32 
33 Statistical heterogeneity was assessed by considering the chi-squared test for significance at 
34 
35 p<0.1 and I-squared inconsistency statistic of >50% to indicate significant heterogeneity. 
36 Where significant clinical heterogeneity was present, analysis of individual studies and/or 









47 General Principles statements 
49 
50 GRADE recommends that where certain principles of diagnosis and treatment of a disease 
51 
52 are generally agreed by the medical community, these should be stated in terms of “good 
53 practice statements”(23). Here we call these “General Principles” and are a description of 
55 generally-accepted best medical practice as evidenced by consensus within our Guideline 
56 
57 Working Group. They are not necessarily evidence-based but form the clinical context 
58 
59 within which the evidence-based recommendations should be understood. 
60 











3 General Principles statements in relation to GCA were drafted and iteratively refined by 
4 
5 means of multiple rounds of email consultation within the Guideline Working Group, 
6 
7 including patient representatives, as well as wider consultation by presentation and 
8 
9 discussion at international rheumatology meetings. The final versions were voted on by the 
10 
11 Working Group and a consensus score generated for each statement, defined as the mean 




17 Forming guideline recommendations 
18 
19 
Using the Evidence Profiles, recommendations were proposed for each key question 
21 according to the GRADE methodology(24): 
22 
23 
24 The GRADE system offers two grades of recommendations: “strong” and “conditional”. 
25 
26 This grade is determined by 1) QoE, 2) balance between desirable and undesirable effects, 
27 
28 3) values and preferences of patients, and 4) use of resources. 
29 
30 The evidence on prognostic factors was used to build subgroups of GCA patients with 
31 
32 different risk profiles concerning patients’ important outcomes rather than formulating 
33 
34 individual recommendations on prognostic factors. Treatment recommendations have been 
35 
36 tailored to these subgroups given that the tradeoff between benefit and harm, values and 
37 preferences as well as consideration regarding resource use may vary according to the 
39 presence or absence of risk factors. 
40 
41 
42 The recommendations process was conducted in two stages: 
43 
44 I) The quality of evidence was discussed at international meetings and webinars 
45 
46 II) Recommendations were formulated which were iteratively refined via webinars 
47 
48 and email. 
49 
50 Finally, the Working Group voted by scoring each recommendation on a 0-10 scale. The 
52 consensus score was defined as the mean of all scores received. 
53 
54 
55 The quality of overall evidence for each recommendation was summarised using the GRADE 




















The following electronic databases were searched from their inception dates, noted in 
9 parentheses, to present: Ovid MEDLINE (1946), EMBASE (1988), Cochrane Central Register 
10 
11 of Controlled Trials (1996), and Cochrane Systematic Reviews (1993). The search was last 
12 
13 updated on 23rd June, 2018. 
14 
15 Because of the need for quality appraisal by a consistent team of reviewers, the search was 
16 









26 The Guideline will be updated after three years; publication of a major new clinical trial may 
27 









37  Patients with suspected giant cell arteritis (for diagnostic tests) 
38 
39 




44  Takayasu arteritis 
46 
47  Polymyalgia rheumatica (unless there is also a diagnosis of giant cell arteritis) 
48 
49 




54 “General Principles” are not the same as evidence-based recommendations, but are 
55 
56 presented here to summarise best practice. 
57 
58 
59 How should suspected GCA be treated? 










3 1. Patients in whom GCA is strongly suspected should be immediately treated with 
4 
5 high-dose glucocorticoids. Consensus score: 9.61 
6 
7 
8 “Strongly suspected” GCA means that in the assessing clinician’s judgement, GCA is a more 
9 
10 likely explanation for the patient’s symptoms than any other condition. The assessing 
11 clinician may take into account GCA symptoms, signs and laboratory tests (such as acute 
13 phase markers) (25, 26). The risk of toxicity caused by short-term glucocorticoid treatment 
14 
15 commenced in patients with initial strong suspicion of GCA but then diagnosed with an 
16 
17 alternative condition, is acceptably low as long as a full diagnostic evaluation is performed 
18 
19 promptly and it is acknowledged that a suspicion of GCA is not the same as a diagnosis of 
20 
21 GCA. For doses, see below. 
22 
23 
24 How quickly should patients with suspected GCA be referred for evaluation? 
25 
26 2. GCA is a medical emergency. Each local healthcare organisation should have 
27 
28 information available to front-line clinicians, such as general practitioners and 
29 
30 clinicians working in acute care, on how to refer patients with suspected GCA 
31 
32 urgently for local specialist evaluation: patients should be evaluated by a specialist 
33 ideally on the same working day if possible and in all cases within 3 working days. 
35 Consensus score: 9.17. 
36 
37 
38 Rapid specialist evaluation is a key principle of management of GCA; therefore, “fast-track” 
39 
40 referral pathways for urgent specialist evaluation of suspected GCA are beneficial. On 
41 
42 suspicion of GCA, primary care providers should initiate glucocorticoids alongside an urgent 
43 referral to the local GCA pathway. In retrospective reports from centres that have set up 
45 “fast-track” referral pathways, initial diagnostic evaluation and treatment of patients with 
46 
47 suspected GCA within 24 hours of referral has been associated with reduction of reported 
48 
49 rates of GCA-related sight loss, compared to conventional care pathways(27, 28). In a 
50 
51 prospective, multicentre UK study, clinical evaluation, vascular ultrasound and temporal 
52 
53 artery biopsy were all undertaken within one week of commencing high-dose glucocorticoid 
54 therapy for suspected GCA (19). The success of “fast-track” referral pathways depends on 
56 appropriate selection of patients for referral, and therefore education of clinicians in 
57 
58 primary and secondary care is crucial. 
59 
60 











3 To whom should patients with suspected GCA be referred? 
4 
5 3. Patients with suspected GCA should be evaluated by a clinician with appropriate 
6 
7 specialist expertise, usually a rheumatologist. Patients presenting with a history of 
8 
9 new visual loss (transient or permanent) or double vision should be evaluated as 
10 




15 The reason for needing a full, prompt diagnostic evaluation by a clinician with appropriate 
16 
17 specialist expertise is that undiscerning use of high-dose glucocorticoids may mask other 
18 
19 diseases and can complicate the diagnostic work-up(12, 25). Where the diagnosis is difficult, 
20 
21 opinions from specialists from multiple disciplines can be of value. This includes the 
22 interpretation of specialised investigations for GCA and the consideration of alternative 
24 diagnoses. Ophthalmological evaluation is essential where there is visual loss, of which 
25 
26 there are various possible causes in GCA (29, 30). 
27 
28 
29 What evaluations should be performed when starting treatment? 
30 
31 4. When starting glucocorticoids for suspected GCA, diagnostically relevant symptoms 
32 
33 and signs should be documented. Blood should be taken for full blood count, C- 
34 
35 reactive protein (CRP) and erythrocyte sedimentation rate (ESR) before or 
36 immediately after commencing high-dose glucocorticoids. If GCA is strongly 
38 suspected, the first dose of glucocorticoid can be given without waiting for 
39 
40 laboratory results. Consensus score: 9.61 
41 
42 
43 Diagnostically relevant symptoms and signs of GCA include headache; scalp hyperaesthesia; 
44 
45 jaw or tongue claudication; temporal artery tenderness, nodularity or reduced pulsation; 
46 visual manifestations including diplopia or changes to colour vision; limb claudication; 
48 polymyalgia rheumatica (pain and stiffness of shoulder and hip girdles); fever, sweats or 
49 
50 weight loss. Less commonly, patients may have carotidynia, audiovestibular symptoms, dry 
51 
52 cough, or indications of tongue or scalp ischaemia that may precede necrosis. However, as 
53 
54 none of the above-mentioned symptoms is entirely specific (or pathognomonic) for GCA, 
55 
56 and many are very non-specific, each is of limited use if taken in isolation(26), and the 
57 differential diagnosis must also be considered. GCA causes elevation in platelet count, CRP 
59 and ESR. Plasma viscosity can be used where ESR is unavailable. These markers all fall with 
60 










3 glucocorticoid therapy; therefore, all patients should have blood drawn prior to starting 
4 
5 treatment, unless there is evidence of critical ischaemia such as visual loss or diplopia and 
6 




11 What evaluations should be performed soon after starting treatment for GCA? 
12 5. Patients treated for GCA should be evaluated for features of the disease relevant to 
14 prognosis, such as clinical and laboratory features of a marked inflammatory 
15 
16 response at diagnosis, ischaemic manifestations such as transient visual loss or 
17 
18 jaw/tongue claudication, and signs or symptoms indicating involvement of the aorta 
19 
20 and its proximal branches; and for co-morbidities relevant to treatment, such as 
21 
22 diabetes mellitus, hypertension, and bone fracture risk. Consensus score: 9.53 
23 
24 Assessments to be performed in all patients with GCA are detailed in table 1. As well as 
25 
26 confirmatory tests for GCA (see Key Recommendation 1), alternative explanations for 
27 
28 patients’ symptoms should be considered, particularly if these confirmatory tests are 
29 
30 negative. Factors relating to prognosis (risk factors (prognostic) PICO questions 1-6) were 
31 
32 reviewed; overall, insufficient evidence was found to be able to stratify patients with proven 
33 GCA to different management strategies on the basis of risk factors considered: age, sex, 
35 acute phase reactants, PMR status, large-vessel involvement in GCA, atherosclerotic 
36 
37 disease, glucocorticoid responsiveness or histological features of GCA. Nonetheless these 
38 
39 features remain important diagnostically and/or when assessing for risk of glucocorticoid- 
40 
41 associated adverse effects. 
42 
43 
44 Risk factors for visual loss: Studies reporting risk factors for permanent visual loss in GCA 
45 yield variable results. In a single-centre study of 339 consecutive biopsy-proven cases 
47 presenting over a 39-year period, in which clinical features were prospectively recorded by 
48 
49 an internist in a 176-item structured questionnaire, 53 patients had permanent visual loss. 
50 
51 In multivariable regression modelling, older age, history of transient visual loss and jaw 
52 
53 claudication were independent predictors of visual loss, while fever and rheumatic 
54 
55 symptoms were protective(31). Similar findings were reported in an earlier retrospective 
56 study of irreversible cranial ischaemic complications in 200 patients, with transient diplopia 
58 also identified as a potential risk factor(32). Hypertension and ischaemic heart disease were 
59 
60 also identified as potential risk factors for cranial ischaemic complications in studies from 











3 Italy and Spain(33, 34). In an international multicentre observational study reporting data 
4 
5 from 433 GCA patients from 26 countries, 34 patients developed complete loss of vision in 
6 
7 one or both eyes at 6 months. After adjusting for age and sex, the strongest risk factor for 
8 
9 this was peripheral vascular disease recorded at baseline (the effect size was similar when 
10 
11 restricting the case definition to biopsy proven GCA)(35). 
12 
13 
14 Risk factors for aortic aneurysms: Inflammation of the aorta is associated with subsequent 
15 
16 development of aortic dilatation or aneurysm(36); and those GCA patients with dilatation of 
17 
18 the subclavian arteries were found to be more likely to develop aortic aneurysm later than 
19 
20 those with GCA-related subclavian stenosis(37). Possible risk factors for aneurysm 
21 
22 development in GCA are smoking, male sex, hypertension, and pre-existing cardiovascular 
23 disease as well as inflammation of the aorta or its proximal branches(37-41). However, the 
25 evidence about risk factors for aneurysm development in GCA is not at present sufficient to 
26 
27 define high risk subgroups to select GCA patient subgroups for aortic imaging. Chest 
28 
29 radiography involves minimal radiation exposure but is insensitive to early thoracic aortic 
30 
31 aneurysms(42). French recommendations suggest routine aortic imaging at GCA diagnosis 
32 
33 and every 2-5 years thereafter(43). However, aortic imaging as a routine screening test for 
34 all GCA patients remains of uncertain cost-effectiveness and the optimal method and timing 
36 of imaging in this context is still unclear(44). Therefore clinicians are advised to use their 
37 




42 Risk factors for prolonged treatment course: A “strong inflammatory response” (defined as 
43 three or four of the following features: fever, weight loss, ESR85mm/hour, and 
45 
haemoglobin<11g/dL) has been associated with higher relapse rate and prolonged 
47 treatment course(45-47). Imaging evidence of LV-GCA may be associated with prolonged 
48 
49 glucocorticoid treatment compared with patients with cranial GCA who did not have 
50 
51 imaging evidence of LV-GCA (36, 48). 
52 
53 
54 It is best practice for the prescriber of glucocorticoid therapy to ensure that patients are 
55 
56 evaluated for hypertension and hyperglycaemia (blood glucose for acute changes and/or 
57 HbA1c to identify patients that might be at greater risk) within the first 2 weeks of 
59 commencing high-dose glucocorticoids. Comorbidities relevant to glucocorticoid toxicity 
60 












3 include diabetes mellitus, osteoporosis and bone fracture; generally, toxicity increases with 
4 
5 glucocorticoid dose and duration(49). Symptoms of and/or exposure to serious infections 
6 
7 should be assessed in all patients starting glucocorticoids, considering local prevalence of 
8 
9 these infections; it is suggested that a chest radiograph and dipstick urinalysis should be 
10 
11 performed. Exposure to TB should be discussed and screened according to national 
12 guidelines(50). 
14 
15 Oral glucocorticoids can rarely increase intraocular pressure or worsen pre-existing primary 
16 
17 open angle glaucoma. If there is glaucoma or ocular hypertension present, or history of 
18 
19 being a glaucoma suspect or glaucomatous risk factors (such as connective tissue disease, 
20 
21 type I diabetes, a first-degree relative with primary open-angle glaucoma, or high myopia), 
22 screening should be performed by a suitably trained eye professional(51). 
24 
25 
For ongoing care via a shared care model, patients with GCA should see a clinician with 
27 appropriate expertise at least every 2-8 weeks during the first six months, then every 12 
28 
29 weeks during the second six months, every 12-24 weeks during the second year, and 
30 
31 additionally as indicated in case of relapse or as glucocorticoid therapy is tapered and 
32 
33 discontinued. This visit schedule is based on the higher likelihood of new treatment-related 
34 
35 adverse events and need for treatment dose adjustment early in the treatment course, 
36 while glucocorticoid doses are still high. However, this should be adapted for the individual 
38 patient. Each follow-up visit should include at least a full history, targeted physical 
39 
40 examination and measurement of at least full blood count, ESR and/or CRP, plus follow up 
41 





47 How should ongoing management of GCA be individualised? 
48 6. Full assessment of the disease and co-morbidities, and consideration of the patient’s 
50 personal priorities, should inform decisions about glucocorticoid tapering and 
51 
52 initiation of additional treatments such as glucocorticoid-sparing therapies. 
53 
54 Involvement of, and clear communication with, primary care physicians is critical 
55 
56 especially for management of multimorbidity. Consensus score: 9.67 
57 
58 Management of patients with GCA should include attention to co-morbidities and the 
60 impact of glucocorticoid toxicities in order to individualise the standard glucocorticoid 











3 tapering schedule (Table 2). PICO questions on the prevention of glucocorticoid-induced 
4 
5 osteoporosis and immunisation in GCA were not included; there are published guidelines on 
6 
7 these matters(13, 14). Although it is customary to co-prescribe proton pump inhibitors with 
8 
9 high-dose glucocorticoid therapy, especially in older patients, it has recently been suggested 
10 
11 that lower glucocorticoid doses may not always routinely need co-prescription of a proton 
12 pump inhibitor(52). Local or national guidance should be followed. Glucocorticoid therapy 
14 increases susceptibility to infections but may also decrease the efficacy of vaccinations; live 
15 
16 vaccines are contra-indicated in patients receiving high-dose glucocorticoid therapy (>20 mg 
17 
18 prednisolone daily for 2 weeks or longer)(53). Patients without a history of chicken pox 
19 
20 (varicella zoster virus infection) should be advised to avoid close contact with people who 
21 
22 have chickenpox or shingles, and to seek urgent medical advice if they have been exposed. 
23 
24 
25 What education should patients be offered? 
26 7. All patients with GCA should be provided with information about GCA and its 
28 treatment. Patients should receive advice on diet, physical activity and stopping 
29 
30 smoking. Consensus score: 9.47. 
31 
32 
33 Information should be available at least in written format and ideally in multiple formats. 
34 Dietary considerations include mitigating the potential effects of glucocorticoid therapy on 
36 body weight, post-prandial glycaemia and bone fracture risk. Recommendations on physical 
37 
38 activity in inflammatory arthritis and osteoarthritis are available (54) and there have also 
39 
40 been suggestions of benefit in other inflammatory vascular diseases(55) but advice needs to 
41 
42 be tailored to the individual patient with GCA, particularly if there are comorbidities. 
43 
44 Particular considerations in GCA may include physical deconditioning as a result of the 
45 inflammatory disease, vascular stenosis to the limbs and the role of exercise in stimulating 
47 collateral formation, and the psychological benefits of exercise in mitigating the impact of 
48 
49 the disease on the patient. Particular considerations with patients receiving long-term 
50 
51 glucocorticoid treatment may include myopathy, which typically develops after weeks or 
52 
53 months of glucocorticoid therapy (particularly at high doses); insulin resistance limiting the 
54 
55 ability of skeletal muscle to take up glucose and store glycogen; bone fragility; and central 
56 adiposity. Exercise can also be beneficial for improving balance and general mobility, which 
58 may be affected by alterations to vision and biomechanics. The role of exercise programmes 
59 
60 in GCA has not been formally evaluated in clinical studies. Patients should be signposted to 







3 relevant patient support groups or charities as sources of peer support. Patients should be 
4 
5 advised of potential symptoms of glucocorticoid withdrawal, although these are uncommon 
6 
7 in practice. Patients should be advised about alteration of glucocorticoid dose in 
8 
9 intercurrent illness, especially including advice for seeking emergency attention if they 
10 
11 suffer a vomiting illness necessitating parenteral glucocorticoid. 
12 
13 
14 What plans should be made for possible future GCA relapses? 
15 
16 8. During glucocorticoid taper and after glucocorticoid cessation, patients should be 
17 
18 informed what symptoms may suggest GCA relapse and what action the patient 
19 
20 should take in these circumstances, including first point of contact for medical advice 
21 
22 and how to contact the team providing specialist care. Consensus score: 9.81 
23 
24 Examples of actions to consider if new GCA-attributable symptoms develop are given in 
25 





31 Specific recommendations for diagnostic tests in suspected GCA 
32 
33 
34 As affirmed in the 2010 BSR/BHPR guideline, there is an urgent need for confirmation of 
35 
36 disease in every suspected case of GCA (10). In the 2010 guidance, it was recommended 
37 that temporal artery biopsy (TAB) was desirable in every case of suspected GCA. In this 
39 edition, this recommendation has been updated in view of new evidence regarding imaging 
40 




45 Which additional confirmatory diagnostic tests should be performed in all patients with 
46 




51 Diagnostic accuracy may be expressed as sensitivity or specificity, or as likelihood ratios; this 
52 
53 information can be combined with the pre-test probability (established on clinical grounds) 
54 
55 to select and interpret the results of confirmatory diagnostic tests. Compared to biopsy, 
56 
57 imaging tests such as ultrasound have the advantage of access to both superficial temporal 
58 
59 arteries in their entirety. Most diagnostic accuracy studies have focused on the role of 
60 











3 ultrasound (n=16) or MRI (n=7). One study addressed the role of FDG-PET, and another 
4 
5 study examined the role of FDG-PET and CT angiography for GCA diagnosis. 
6 
7 
Seven studies (519 patients with suspected GCA, of whom 169 were diagnosed with GCA) 
9 compared the ultrasound ‘halo’ sign with a clinical diagnosis of GCA, giving a pooled 
10 
11 sensitivity of 79% (95% CI: 73%-84%) and pooled specificity of 94% (95% CI: 90%-96%) (56- 
12 
13 62). Quality of evidence (QoE) was +++; downgrading was performed because of risk of bias 
14 




19 Five studies (185 patients with suspected GCA, of whom 57 were diagnosed with GCA) 
20 
21 compared the ultrasound ‘halo’ sign with temporal artery biopsy, giving a pooled sensitivity 
22 
23 of 74% (95% CI: 63%-83%) and pooled specificity of 81% (95% CI: 73%-88%) (60-64). QoE 
24 
was +; downgrading was performed because of high risk of bias in all 5 studies, and because 
26 of inconsistency. Patients with LV-GCA were not evaluated in these studies. 
27 
28 
29 Two studies (140 patients with suspected GCA, of whom 67 were diagnosed with GCA) 
30 compared the ultrasound ‘compression’ sign of temporal arteries with ACR criteria-based 
32 diagnosis of GCA, giving a pooled sensitivity of 79% (95% CI: 67%-88%) and a pooled 
33 
34 specificity of 100% (95% CI: 95-100) (56, 65). QoE ++; downgrading was performed for risk of 
35 
36 bias in one of the studies, and for the fact that both studies were performed by the same 
37 
38 research group. The ACR criteria for GCA, which are not suitable for clinical diagnosis, served 
39 
40 as reference standard in both studies. 
41 
42 Three studies (560 patients with suspected GCA, of whom 327 had a clinical diagnosis of 
43 
44 GCA) compared the diagnostic performance of ultrasound abnormality (defined as any one 
45 
46 of halo, stenosis or occlusion) with clinical diagnosis of GCA, giving a pooled sensitivity of 
47 61% (95% CI: 56%-67%) and pooled specificity of 86% (95% CI: 81%-90%) (19, 62, 66). QoE 
49 ++; downgrading was performed for risk of bias in all three studies, and for inconsistency. 
50 
51 
52 Four studies (563 patients with suspected GCA, of whom 180 had a positive temporal artery 
53 biopsy) compared the diagnostic performance of ultrasound abnormality (defined as any 
55 one of halo, stenosis or occlusion) with temporal artery biopsy, giving a pooled sensitivity of 
56 



















Neither clinical diagnosis nor temporal artery biopsy are perfect reference standards for 
9 evaluating the diagnostic accuracy of ultrasound for GCA, because neither of these are 
10 
11 themselves 100% accurate. Clinical diagnosis is based on clinical symptoms, signs and 
12 
13 laboratory tests, each of which are imperfect markers for GCA. 
14 
15 A positive temporal artery biopsy, showing features of inflammation characteristic of GCA 
16 
17 such as giant cells or panarteritis(68), confirms the diagnosis of GCA. Although the true 
18 
19 sensitivity of temporal artery biopsy is not precisely known, it is accepted that its sensitivity 
20 
21 is substantially less than 100%; this is supported by the histological observation of skip 
22 
23 lesions in some cases. An imperfect reference standard would result in underestimation of 
24 the diagnostic accuracy of ultrasound. When using clinical diagnosis as a reference standard 
26 it is important that this is made independently of the index test result in order to avoid bias; 
27 
28 this may be done by blinding of the diagnostician to the index test result. Notably a large 
29 
30 prospective UK study assessing the diagnostic value of ultrasound addressed this issue by 
31 
32 blinding the patient, the treating clinician and the investigator to the ultrasound result (19). 
33 
34 Ultrasound was found to be more sensitive but less specific than biopsy for diagnosis of 
35 GCA, was cost-effective and provided scope for reducing the number of patients who need a 
37 temporal artery biopsy(19). Overall, the pooled positive and negative likelihood ratios for 
38 
39 ultrasound appear to support its use either for ruling out GCA in low-probability cases or for 
40 
41 confirming GCA in high-probability cases (Appendix E and Figure 1). Ultrasound of the 
42 




47 Six studies (500 patients with suspected GCA, of whom 268 were finally diagnosed with 
48 
49 GCA) compared cranial artery MRI (vessel wall oedema and contrast enhancement) with 
50 
51 clinical diagnosis, giving a pooled sensitivity of 75% (95% CI: 69%-80%) and a pooled 
52 specificity of 89% (95% CI: 84%-93%) (70-75). QoE ++; downgrading was performed for risk 
54 of bias in five of the studies, and for the fact that five of the six studies were performed by 
55 
56 the same research group; sensitivity was somewhat lower in the study performed by a 
57 
58 separate group(75). 
59 
60 











3 Five studies (397 patients with suspected GCA, of whom 171 had positive temporal artery 
4 
5 biopsy) compared cranial artery MRI (vessel wall oedema and contrast enhancement) with 
6 
7 temporal artery biopsy, giving a pooled sensitivity of 94% (95% CI: 90%-97%) and specificity 
8 
9 of 79% (95% CI: 73%-84%) (70-73, 75). QoE +; downgrading was performed for risk of bias in 
10 
11 five of the studies, for inconsistency, and for likely publication bias. 
12 
13 Overall, MRI of the cranial arteries appears to be potentially useful for ruling out GCA if the 
14 
15 result if negative, but false positive test results could occur, such that MRI of the cranial 
16 
17 arteries would not be first choice for a confirmatory test in GCA(75). Other issues of 
18 relevance to cranial vascular MRI are low availability of high-resolution 3T MRI equipment 
20 and expertise, higher costs and possible adverse effects of contrast agents. 
21 
22 
23 In contrast to the 2010 guideline, where the authors outlined that imaging techniques are 
24 promising for diagnosis and monitoring of GCA(10), in this guideline there is now sufficient 
26 evidence, taken together, to state that all patients with GCA should have at least one 
27 
28 confirmatory diagnostic test, which could be either temporal artery biopsy, or temporal and 
29 
30 axillary artery ultrasound. However, temporal artery biopsy and ultrasound differ in their 
31 
32 positive and negative likelihood ratios for GCA, with biopsy having relatively greater “rule- 
33 
34 in” value and ultrasound having relatively greater “rule-out” value (Appendix E). Selection of 
35 the most appropriate confirmatory diagnostic test(s) therefore requires an assessment of 
37 the pre-test probability as outlined elsewhere(76); if both ultrasound and biopsy are 
38 
39 possible, an approach to this is suggested in Figure 1. 
40 
41 The ultrasound halo diminishes in size during the first week of glucocorticoid therapy, 
43 indicating that sensitivity of the test is likely to depend on the delay between initiation of 
44 
45 glucocorticoid therapy and the ultrasound test(19). Ultrasound is operator-dependent and 
46 
47 requires adequate training. Ultrasound performs best in the “fast-track” setting, assuming 
48 
49 rapid access, good technical equipment and high expertise with this method. With 
50 
51 ultrasound, the non-compressible ’halo’ sign is the most important finding suggesting 
52 GCA(77). Temporal artery biopsy should be performed by a surgeon experienced in this 
54 procedure, and samples should be at least 1cm in length post-fixation. The pathologist 
55 
56 evaluating the biopsy should be experienced in diagnosing GCA. Data from the TABUL 
57 
58 study(19) suggested significant variation between pathologists in the interpretation of 
59 
60 temporal artery biopsy histology, so where biopsy findings are ambiguous (eg low-level 











3 inflammation restricted to the adventitia), discussion between the requesting clinician and 
4 
5 the pathologist is desirable. In the absence of inflammatory infiltrate, a report of healed 
6 
7 arteritis is not sufficient to diagnose GCA. Isolated vasa vasorum vasculitis is not diagnostic 
8 
9 of GCA. Contralateral biopsy may slightly increase the yield of temporal artery biopsy, but is 
10 
11 usually unnecessary. Biopsy may remain positive for several weeks after initiation of 
12 glucocorticoid therapy (78). 
14 
15 If neither vascular ultrasound nor biopsy is possible, and local MRI facilities and radiology 
16 
17 support are available, then high-resolution 3 Tesla MRI of the cranial arteries could be used 
18 instead. In interpreting the results of these diagnostic tests, pre-test probability (established 




24 1. Strong recommendation: Patients with suspected GCA should have a confirmatory 
25 
26 diagnostic test. This could be either a temporal artery biopsy at least 1cm in length, or 
27 




32 Which tests can be used to evaluate involvement of the aorta and its proximal branches in 
33 




38 One study (24 patients with suspected GCA, of whom 15 were diagnosed with GCA) 
39 compared FDG-PET with clinical diagnosis of GCA, giving a sensitivity of 67% (95% CI: 38%- 
41 88%) and a specificity of 100% (95% CI: 66% to 100%) (79). QoE ++; downgraded because of 
42 




47 One study (69 patients with suspected GCA/PMR, of whom 13 had biopsy evidence of GCA) 
48 
49 compared vascular 18F-glucose uptake in thorax and legs on FDG-PET with temporal artery 
50 biopsy, giving a sensitivity of 77% (95% CI: 46% to 95%) and specificity of 66% (95% CI: 52% 
52 to 78%). Comparing vascular 18F-glucose uptake in thorax on FDG-PET with temporal artery 
53 
54 biopsy gave a sensitivity of 54% (95% CI: 25% to 81%) and specificity of 86% (95% CI: 74% to 
55 
















3 One study (24 patients with suspected GCA, of which 15 were diagnosed with GCA) 
4 
5 compared CT angiography (CTA) with clinical diagnosis of GCA, giving a sensitivity of 73% 
6 
7 (95% CI: 45%-92%) and specificity of 78% (95% CI: 40%-97%) (79). QoE++; downgraded for 
8 
9 indirectness and publication bias. CTA can reveal wall thickening with contrast enhancement 
10 
11 in biopsy-proven GCA(81). There is also experience with CTA for accurate assessment of 
12 luminal diameter for large vessel stenosis in Takayasu arteritis (82). 
14 
15 
16 No studies of MR angiography for the diagnosis of LV-GCA were found meeting our criteria, 
17 
18 but there is experience with MRI for detection of vessel wall oedema reflective of 
19 
20 inflammation and accurate assessment of luminal diameter for large vessel dilatation and 
21 
22 stenosis in diseases of the major arteries, such as Takayasu arteritis. Gadolinium-enhanced 
23 MR angiography may help identify aortitis in the large-vessel vasculitides, but appears to be 




29 In addition to showing inflammation of the large vessels, FDG-PET-CT may detect 
30 
31 malignancy or infection so can be of use in the differential diagnosis of GCA. Contrast- 
32 
33 enhanced CT of the chest and abdomen is also often used in clinical practice to screen for 
34 deep infection or occult malignancy. Moreover, aortic wall thickening on a contrast CT might 
36 help to identify GCA, albeit with lower sensitivity than FDG-PET-CT, and could also 
37 
38 potentially have uses in settings where FDG-PET-CT is unavailable(79, 84, 85). Additional 
39 
40 advantages of FDG-PET and CT therefore include potential value in the workup of 
41 
42 alternative diagnoses such as malignancy and infection. 
43 
44 
45 As well as detecting axillary artery involvement for diagnosis of large-vessel involvement in 
47 GCA, vascular ultrasound may also be able to visualise the carotid arteries and obtain more 
48 
49 limited views of the subclavian arteries, vertebral arteries, and parts of the aorta, but a 
50 




55 Overall, there is indirect evidence for the use of imaging tests to evaluate involvement of 
56 the aorta and its proximal branches in GCA, but the published evidence is extrapolated from 
58 other diseases such as Takayasu arteritis(76) and there is currently insufficient evidence 
59 
60 










3 from prospective studies of suspected GCA to yield precise estimates of diagnostic accuracy 
4 




9 2. Conditional recommendation: 18F-fluorodeoxyglucose positron emission tomography 
10 
11 (FDG-PET), magnetic resonance angiography (MRA), computed tomography 
12 angiography (CTA) or axillary artery ultrasound may be used to evaluate involvement 





19 Recommendations for treatment of GCA 
20 
21 
22 What is the best dose and route of initial glucocorticoid therapy for GCA in the absence of 
23 




There are no clinical trials comparing different initial oral glucocorticoid doses for GCA. 
29 However, clinical experience suggests that the vast majority of patients with GCA respond 
30 
31 symptomatically within 1-7 days to a 40-60mg daily dose of prednisolone, apart from 
32 
33 irreversible sequelae such as established visual loss, stroke or tissue necrosis. Failure to 
34 




In several clinical trials(86-88) the initial dose of oral prednisolone has been administered by 
40 weight rather than by a fixed dose, as is done for other systemic vasculitides in clinical 
41 
42 practice. There was not enough direct evidence to be able to recommend dosing 
43 
44 prednisolone strictly by mg/kg, but nonetheless body weight (or at least size) remains a 
45 
46 factor to be taken into account when deciding on an initial dose. Comorbidities also should 
47 
48 be taken into account, since the toxicity of glucocorticoid therapy increases with dose(49). 
49 Clinicians should consider a higher dose within the 40-60mg range for patients who have 
51 cranial ischaemic features of GCA such as ischaemic visual manifestations, jaw or tongue 
52 




57 Two RCTs addressed the question of whether intravenous glucocorticoids should be given in 
58 
59 patients with new-onset, uncomplicated GCA (i.e. those without any history of recent visual 
60 










3 loss, amaurosis fugax or transient ischaemic attack): one single-centre, 78-week double 
4 
5 blinded RCT (n=27) and one 12-month open RCT (n=164)(86, 89). In the double blinded 
6 
7 RCT(89), patients received either 15mg/kg body weight/day intravenous 
8 
9 methylprednisolone for 3 days or placebo plus 40mg/day oral prednisone. In the open 
10 
11 RCT(86), the intervention group was treated with a single dose of 240mg intravenous 
12 methylprednisolone followed by 0.7mg/kg oral prednisone; one control group was treated 
14 with oral prednisone 0.7mg/kg alone, and a further control group was treated with a single 
15 
16 dose of 240mg intravenous methylprednisolone followed by 0.5mg/kg oral prednisone. Due 
17 
18 to the substantial differences in study design, efficacy outcomes were not meta-analyzed. 
19 





Moderate QoE (+++) from one study(89) suggested a reduction of the cumulative 
26 glucocorticoid dose at week 78 (median cumulative glucocorticoid dose 5,636mg 
27 
28 (interquartile range 4,050-6,690mg) in the group that received three days of intravenous 
29 
30 methylprednisolone group, compared to 7,860mg (interquartile range 7,373-9,005mg) in 
31 
32 the control group). The glucocorticoid pulses were not counted for cumulative dose. In the 
33 
34 other study, very low QoE (+)(86) indicated no benefit of pulse treatment at 1, 2, 6 and 12 
35 months regarding cumulative glucocorticoid dose. 
37 
38 Low QoE (++) suggested that those in the methylprednisolone group had a higher 
39 
40 probability of achieving remission while receiving 5mg oral prednisone or less at three 
41 
42 timepoints: week 36 (RR 4.64, CI 1.24-17.33), week 52 (RR 5.11, 1.39-18.81) and week 78 
43 
44 (RR 2.57, CI 1.12 to 5.89)(89). 
45 
46 
47 No differences were found between pulse therapy and control groups as regards 
48 discontinuation of glucocorticoids at 12 months (QoE +)(86), patients with at least 1 relapse 
50 at 78 weeks and drug-free remission at 78 weeks (both with QoE ++)(89). 
51 
52 
53 Comparing adverse events between treatment arms in these trials, no differences were 
54 
55 observed between intervention and control groups regarding infections, cushingoid habitus, 
56 
57 psychiatric side effects, cardiovascular complications, diabetes, digestive disturbances, 
58 
59 glucocorticoid-related ophthalmologic side effects, phlebitis/thrombosis, glucocorticoid 
60 










3 induced myopathy, abdominal bleeding, osteoporosis including fractures and mortality (all 
4 
5 with QoE + or ++). Nonetheless, the small size of these two trials limits power to show 
6 
7 significant differences in adverse events between treatment arms. 
8 
9 
10 In summary, there may possibly be a small benefit in terms of a reduced cumulative 
11 
12 glucocorticoid dose in patients receiving glucocorticoid intravenous pulse therapy, but due 
13 to concerns over the likely increased risk of adverse effects with this therapy, the value of 
15 intravenous glucocorticoids in patients without acute or intermittent visual loss in GCA 
16 




21 3. Conditional recommendation: The standard initial glucocorticoid dose for GCA is 40- 
22 60mg oral prednis(ol)one per day. QoE: + Consensus score: 9.44. 
24 
25 What is the best dose and route of initial glucocorticoid therapy for GCA in the presence of 
26 




31 Clinical trials have not been conducted in patients with acute ocular ischaemia, but 
32 
33 observational data indicates that the vast majority of visual loss in GCA occurs before 
34 initiation of glucocorticoid therapy. Acute visual loss due to ocular ischaemia in GCA 




40 Intravenous glucocorticoid (methylprednisolone) therapy is used in systemic vasculitis for 
41 
42 the treatment of life- or organ-threatening disease(90). The intravenous formulation assures 
43 
44 rapid delivery of the drug to the site of action and in addition the very high doses required 
45 have rapid actions via non-genomic effects, in addition to the genomic effects which take 
47 some hours to affect gene transcription(91, 92). Intravenous glucocorticoid therapy is thus 
48 
49 commonly used for patients with acute or intermittent visual loss due to GCA. If intravenous 
50 
51 glucocorticoid therapy is not possible, 60-100mg oral prednisolone may be given for up to 3 
52 
53 consecutive days. 
54 
55 
56 4. Conditional recommendation: GCA patients with acute or intermittent visual loss may 
57 
58 initially be given 500mg – 1g intravenous methylprednisolone daily for up to 3 
59 
60 consecutive days before commencing oral prednis(ol)one therapy. If intravenous 










3 therapy is not immediately possible, this should not delay initiation of oral 
4 




9 How should glucocorticoid dose be tapered in GCA? (PICO 5) 
10 
11 
12 One single-centre, open, 2-month RCT compared different tapering regimens in 35 patients 
13 
14 with new onset GCA(93). The same glucocorticoid dose was used in the first five days, but 
15 the rate of tapering thereafter differed between treatment groups. No significant difference 
17 was found between the groups at 2 months concerning relapse rate (QoE +) or visual loss 
18 
19 (QoE ++). 
20 
21 
22 In a multicentre RCT of tocilizumab as a glucocorticoid-sparing therapy for GCA(94), in two 
23 
24 arms of the trial patients received placebo rather than tocilizumab. In one of these trial 
25 
26 arms prednisone was tapered to zero over 6 months, and in the other of these trial arms 
27 prednisone was tapered to zero over 12 months; relapses were treated at the discretion of 
29 the investigator. Patients with new-onset GCA receiving the 6-month prednisone taper 
30 
31 without tocilizumab had a numerically higher frequency of relapse during the first year than 
32 
33 receiving the 12-month prednisone taper, whereas the cumulative glucocorticoid dose was 
34 
35 similar in these two trial arms. Although patients and investigators were blinded to the 
36 
37 tapering regimen, however, this trial was not designed specifically to compare different 
38 prednisone tapering regimens. 
40 
41 
5. Conditional recommendation: Glucocorticoid dose should be tapered to zero over 12- 
43 18 months, providing there is no return of GCA symptoms, signs or laboratory markers 
44 
45 of inflammation. A more rapid dose reduction is appropriate for patients at high risk of 
46 
47 glucocorticoid toxicity and/or those receiving concomitant glucocorticoid-sparing 
48 


























7 One single-centre, open RCT with unclear length of follow-up compared the effects of 15mg 
8 
9 oral prednisone every 8 hours with single administration of 45mg oral prednisolone/day. A 
10 
11 third (alternate day) group received 90mg oral prednisone every other day. Patients in all 
12 three groups were treated for the first 5 days with 20mg oral prednisone every 8 hours(95). 
14 
15 Remission and relapses at 4 weeks did not differ between groups of split-dose and single- 
16 
17 dose prednisone treatment (QoE +). No difference was reported regarding hypercortisolism 
18 
19 (which was not further defined), fractures, diabetes and glucocorticoid-induced myopathy 
20 
21 (all with QoE +). 
22 
23 
24 Comparing the single-daily and alternate-day treatment groups, at 4 weeks the single-daily 
25 group had higher remission rates at 4 weeks (RR 2.67, CI 1.32-5.39) and lower relapse rates 
27 (RR 0.11, CI 0.02-0.80) (QoE +). Hypercortisolism was more common in the single-daily 
28 
29 group (RR 5.95, CI 1.57-22.57); fractures, diabetes and glucocorticoid-induced myopathy (all 
30 
31 with QoE +) did not differ between groups. 
32 
33 
34 This evidence, albeit low quality, raises concerns that alternate-day dosing may be 
35 
36 associated with a higher relapse risk. Splitting the dose over the day does not seem to 
37 confer benefit, and potentially carries risks of disturbance of diurnal rhythms, including 
39 sleep(96, 97). In summary there appears no reason in GCA to alter the standard guidance in 
40 
41 other medical conditions to prescribe glucocorticoids as a single daily dose in the morning 
42 




47 6. Conditional recommendation: Patients should be prescribed a single daily dose of 
48 glucocorticoid, rather than alternate day dosing or divided daily dosing. QoE: + 



























8 There was neither RCT data nor sufficient clinical experience to make any recommendation 
9 
10 about modified release prednisone in GCA. 
11 
12 
13 7. No recommendation can be made for the use of modified release prednisone in the 
14 treatment of GCA. QoE: insufficient evidence. Consensus score: 9.72. 
16 
17 When should further, non-biologic immunosuppression be added to glucocorticoid therapy 
18 




23 The effect of methotrexate (MTX) has been investigated in 3 RCTs: a single-centre, 24- 
24 month, double-blinded RCT (n=42) of patients with recent onset GCA compared the addition 
26 of MTX 10mg/week, versus placebo, to oral prednisone (initial prednisone dose of 
27 
28 60mg/day)(98). A multicentre, 12-month double-blinded RCT (n=98 instead of 300 originally 
29 
30 planned) of patients with recent onset GCA compared the addition of MTX 15mg/week, 
31 
32 versus placebo, to oral prednisone (initial prednisone dose of 1 mg/kg/day)(87). A smaller 
33 
34 single-centre, double-blinded RCT (n=21), of patients with GCA whose prednisone dose had 
35 been reduced to 30mg/day, compared the adjunctive use of MTX 7.5 mg/week vs. placebo; 
37 the initial glucocorticoid dose was at the discretion of the treating physician and some 
38 
39 patients with visual symptoms received intravenous glucocorticoid pulse therapy(99). 
40 
41 
42 Regarding efficacy data, the two larger trials(87, 98) could be pooled but the smallest 
43 
44 trial(99) was considered separately because it substantially differed from the two other 
45 
46 trials regarding design (lower MTX dose used, initiation of therapy upon reduction of 
47 glucocorticoid dose) and quality. Regarding adverse events, we combined the data from all 
49 three trials events in order to increase the sensitivity to detect rare outcomes. 
50 
51 
52 Pooling of the two larger studies indicated moderate QoE (+++) that MTX reduced the 
53 
54 proportion with relapse at 12-24 months (RR 3.20, 95% CI 1.49 to 6.87)(87, 98); the smallest 
55 
56 trial showed no difference in relapse between the MTX and placebo groups (QoE +)(99). In 
57 
58 addition, the largest trial analysed “treatment failure”, defined as having ≥2 relapses, or 
59 having a relapse that was not controlled by an increment of prednisone dose as scheduled: 










3 regarding this outcome, no difference was seen between the MTX and placebo groups (QoE 
4 
5 ++)(87). In none of the studies was a difference observed regarding cumulative 
6 
7 glucocorticoid dose, or duration of glucocorticoid therapy (all outcomes with QoE + or ++); 
8 
9 however, the largest trial reported only the median and interquartile range of cumulative 
10 
11 glucocorticoid dose, rather than the mean and standard deviation, which reduced the 
12 validity of pooling the published data(87, 98, 99). 
14 
15 Regarding possible modification of glucocorticoid-related adverse effects by MTX: mortality, 
16 
17 vision loss, malignancy, infections, psychiatric side effects, fractures, cataract, diabetes, 
18 
19 hypertension, cushingoid habitus, weight gain and skin fragility did not differ between 
20 
21 groups (data from 1-3 studies, all with QoE + or ++, except for hypertension which revealed 
22 
23 a QoE +++)(87, 98, 99). 
24 
25 
Regarding possible MTX-related adverse effects, there was no strong evidence to support 
27 that MTX was associated either with a higher rate of withdrawal due to any side-effect, nor 
28 
29 an increase in individual side effects including ALT/AST elevation, nausea/vomiting, 
30 
31 thrombocytopenia, oral ulcers, alopecia, diarrhea or gastric discomfort (QoE + or ++)(87, 98, 
32 
33 99). Nonetheless these trials were not designed nor powered to detect differences in 
34 
35 adverse effects. 
36 
37 An individual patient data meta-analysis relating to these three RCTs was also 
39 identified(100) and included in this review because it is a more efficient use of the data than 
40 
41 meta-analysis using published reports. According to the individual patient data meta- 
42 
43 analysis, compared to the placebo group, the MTX group had a modest reduction of the risk 
44 
45 of first and second relapse (hazard ratio (HR) 0.65, p=0.04 and HR 0.49, p=0.02, 
46 
47 respectively), higher rates of glucocorticoid-free remission (HR 2.8, p=0.001 for ≥24 weeks 
48 sustained discontinuation of glucocorticoids) and lower cumulative glucocorticoid doses 
50 (mean difference -1.1g, p=0.007 at week 96)(100). 
51 
52 
53 In summary, the data from these three small RCTs indicate that there might be a modest 
54 
55 benefit of MTX in GCA in reducing relapse and cumulative glucocorticoid dose, and are 
56 
57 encouraging regarding reducing the risk of second relapse as well as first relapse; however, 
58 
59 overall the evidence remains equivocal. MTX has been used at doses of 7.5-15mg weekly in 
60 
















9 One single-centre, 52-week, double-blinded RCT (n=31) compared azathioprine 150mg/day 
10 
11 versus placebo in patients with PMR, with or without GCA, who required ≥5 mg daily oral 
12 prednisolone to control disease activity(101). A lower daily glucocorticoid dose at the end of 
14 the follow-up (52 weeks) was found in the intervention compared to the control group 
15 
16 (mean dose difference 3 mg, CI 4.32-0.28mg, QoE +). Adverse events were similar in both 
17 
18 groups (QoE +). Thirty-one patients were recruited, but only 18 reached the 52-week 
19 
20 timepoint. According to the inclusion criteria for this trial, patients had to satisfy the 
21 
22 Hazleman criteria for PMR. Eleven of 31 of these had a positive temporal artery biopsy. This 
23 trial did not truly fulfil the inclusion criteria for this review (at least 20 patients with GCA) 
25 and therefore no recommendation could be made on the basis of this trial; it is however 
26 
27 included here for completeness since it is frequently mentioned by narrative reviews. 
28 
29 
30 Dapsone was studied at a dose of 50-100mg/day in an open, multicenter RCT (n=47) with 
31 
32 unclear length of follow-up(102). A lower relapse risk was found in the treatment compared 
33 
34 to control group (RR 0.37, CI 0.16-0.84, QoE +), and there was a trend toward a higher 
35 probability of glucocorticoid-free remission (RR 3.81, CI 0.92-15.81, QoE +) in the dapsone 
37 group. Anaemia was more common in the dapsone group compared to the control group 
38 
39 (RR 8.89, CI 1.27-61.99, QoE ++), and the dapsone group had two cases of agranulocytosis. 
40 
41 Rash, diabetes, bone complications, cardiovascular complications, infections and loss of 
42 
43 vision did not differ between groups (all QoE +). 
44 
45 
46 Two open RCTs of ciclosporin (n=82) were published in the format of a letter(103, 104). 
47 Ciclosporin was used at a daily dose of 2.0-3.5mg/kg for 6 or 12 months. No benefit of the 
49 drug was observed regarding cumulative glucocorticoid dose, acute phase reactants as well 
50 
51 as patients’ and physicians’ global assessments (all QoE +). There was, however, an 
52 
53 increased risk of treatment discontinuation due to toxicity (RR 13.00, CI 1.78-95.1, QoE ++). 
54 
55 
56 The potential toxicity of dapsone or ciclosporin is likely to outweigh any possible benefit and 
57 
58 their use is not recommended. 
59 
60 











3 There has been no RCT of leflunomide in GCA despite anecdotal evidence of benefit, case 
4 
5 series and open, non-randomised studies (105-107). In clinical practice, mycophenolate 
6 
7 mofetil or cyclophosphamide have been occasionally used as immunosuppressive agents for 
8 
9 severe GCA by analogy with their use in other systemic vasculitides, but they have not been 
10 
11 formally studied in GCA. 
12 
13 
8. Conditional recommendation: Methotrexate might be considered for GCA, in 
15 combination with a glucocorticoid taper, in patients at high risk of glucocorticoid 
16 
17 toxicity or who relapse. There is insufficient evidence to recommend any other oral 
18 
19 immunosuppressive agent in GCA, including azathioprine, leflunomide or 
20 
21 mycophenolate mofetil. QoE: ++ Consensus score: 8.92. 
22 
23 
Which biologic agents can be used for GCA in addition to standard therapy? (PICO 11, 12) 
25 
26 
Tocilizumab was approved for GCA by the US and European regulatory authorities in 2017 
28 based on the results of two randomised controlled trials of addition of 1 year tocilizumab, or 
29 
30 placebo, to tapering glucocorticoid therapy(88, 94). 
31 
32 
33 In the larger of these trials(94), both patients with new GCA and patients with relapsing GCA 
34 
35 were included. Patients with relapsing GCA had to have been treated for GCA for no more 
36 
37 than 4 years prior to enrolment. Tocilizumab was combined with a standardised prednisone 
38 
39 taper according to which prednisone cessation occurred at 6 months. Patients receiving 
40 placebo were treated with one of two alternative prednisone tapering schedules, by which 
42 prednisone cessation was achieved at either 6 months or 1 year if the patient remained 
43 
44 relapse-free. If a patient relapsed during the study, prednisone therapy was escalated 
45 
46 according to investigator discretion. 
47 
48 
49 The primary endpoint (sustained remission at 1 year plus adherence to the tapering 
50 
51 protocol, using a definition of remission incorporating CRP levels) was achieved in 56% of 
52 
53 patients treated with weekly subcutaneous tocilizumab, and in 53% of those treated every 
54 other week. In the placebo group, sustained remission at 1 year was achieved in 14% of 
56 those tapering prednisone over 6 months and 18% of those tapering prednisone over 1 
57 
58 year. Comparing weekly tocilizumab with placebo plus 6-month glucocorticoid taper, 
59 
60 relative risk (RR) for sustained remission was 4.0 (95 % CI 1.97 to 8.12, QoE++++). 











3 Comparing with other groups revealed similar results, with RR 3.01 - 3.79, QoE ++++. 
4 
5 Patients in the tocilizumab treatment arm also showed a higher rate of sustained remission 
6 
7 using a modified definition of sustained remission that did not require CRP normalisation 
8 
9 (weekly tocilizumab compared with placebo plus 6-month glucocorticoid taper: RR 2.95, 
10 
11 95% CI 1.66 - 5.26, QoE +++, for other comparisons RR 1.65 – 2.76, QoE+++). In both this 
12 trial and in the smaller single-centre trial(88), an increase in relapse-free survival at 1 year 
14 (RR 3.57, 95% CI 2.29 - 5.55, QoE ++++) was seen, and a reduction in 1-year cumulative 
15 
16 glucocorticoid dose was observed in the tocilizumab treatment arms (mean difference 1434 
17 
18 mg lower (95% CI 2148 mg lower to 720 mg lower) in the weekly tocilizumab group 
19 
20 compared to placebo plus 6 month tapering of glucocorticoids, QoE++++; mean difference 
21 
22 from 1434mg to 1956 mg in other comparisons, QoE++++). Patient-reported outcomes were 
23 encouraging although these were assessed using generic measures, since no disease-specific 
25 patient-reported outcome has yet been fully validated for GCA. Of note, although 
26 
27 glucocorticoid-sparing efficacy was demonstrated, these studies were not designed or 
28 
29 powered to demonstrate a reduction in glucocorticoid-related adverse events. 
30 
31 
32 It has been argued that a glucocorticoid-sparing therapy such as tocilizumab would be more 
33 
34 cost-effective in the following GCA patient subgroups: firstly, GCA patients requiring 
35 
36 escalation of glucocorticoid therapy due to relapse of disease, and secondly, GCA patients 
37 who are at high risk for adverse effects from further glucocorticoid treatment (e.g. on the 
39 basis of comorbidity profile or other risk factors for glucocorticoid-related toxicity: for 
40 
41 example, neuropsychiatric glucocorticoid-related adverse effects, previous fragility 
42 
43 fractures, or difficult-to-control diabetes mellitus). UK prescribers should be aware that, at 
44 
45 the time of writing, a limited duration of tocilizumab therapy for GCA has been approved by 
46 
47 the Scottish Medicines Consortium and by NHS England for defined patient groups taking 
48 into account cost-effectiveness data available at the time of the technology appraisal. 
50 
51 
Tocilizumab has only been approved for weekly subcutaneous use, although it has also been 
53 studied in intravenous formulation(88). In the multicentre RCT (94) one of the treatment 
54 
55 arms received subcutaneous tocilizumab every 2 weeks, rather than weekly; patients in this 
56 
57 treatment arm also reached the primary endpoint, although it appeared to be less 
58 
59 efficacious in relapsing patients. The trials in GCA have not demonstrated an increased risk 
60 









3 of adverse events with tocilizumab(88, 94); pooling of data from both trials indicated a 
4 
5 lower rate of serious adverse events in patients treated with tocilizumab than those treated 
6 
7 with placebo (RR 0.64, 95% CI 0.41 to 1.00, QoE+++). 
8 
9 
10 Abatacept was studied in a single, small trial(108). All patients received abatacept initially in 
11 
12 addition to glucocorticoid therapy. Those achieving remission were randomized in week 12 
13 
14 to either continue the drug or to switch to placebo. Time-to-relapse analysis, which was the 
15 primary endpoint, significantly favoured abatacept. A post-hoc analysis to compare the 
17 proportion of patients in remission at 12 months did not show a significant difference 
18 
19 between the treatment arms (RR 1.50 CI 0.71 - 3.17, QoE++), likely due to the small size of 
20 
21 the study. At present abatacept is not approved for treatment of GCA. 
22 
23 
24 TNF inhibitors have been studied in two randomised controlled trials(109, 110), both of 
25 
26 which showed inefficacy but an increased incidence of infections. A third, small RCT of 
27 
28 etanercept for GCA (111) did not fulfil the inclusion criteria for the literature review; 
29 although it showed a lower cumulative glucocorticoid dose in the etanercept arm, this trial 
31 failed to show a significant result for its primary outcome. Based on this evidence, TNF 
32 
33 inhibitors cannot be recommended for GCA. 
34 
35 
36 9. Strong recommendation: Tocilizumab can be considered for GCA, in combination with a 
37 
38 glucocorticoid taper, especially in patients at high risk of glucocorticoid toxicity or who 
39 
40 relapse. TNF inhibitors are not recommended in GCA. QoE: +++ Consensus score: 9.61. 
41 
42 
43 Should anticoagulant or antiplatelet agents be given for GCA? (PICO 12-15) 
44 
45 
46 No RCTs relating to aspirin or other anticoagulant/antiplatelet agents were found. A Cochrane 
48 review found no evidence from RCTs to determine the safety and efficacy of low-dose aspirin 
49 
50 as an adjunctive treatment in GCA(112). National and society guidelines for the secondary 
51 
52 prevention of coronary and other atherosclerotic vascular diseases should be followed. 
53 
54 
55 10. The routine use of antiplatelet or anticoagulant agents for GCA is not recommended. 
56 




















7 No RCTs of cholesterol-lowering agents for GCA were found. National and society guidelines 
8 
9 for the secondary prevention of coronary and other atherosclerotic vascular diseases should 
10 
11 be followed. 
12 
13 
14 11. The routine use of cholesterol-lowering agents such as statins for GCA is not 
15 
16 recommended. QoE: insufficient evidence. Consensus score: 9.53 
17 
18 














Potential organizational barriers to implementation 
35 
36 In practice, constraints of the healthcare system may create challenges to widespread 
37 
38 implementation of this guideline. For example, implementing rapid-access vascular 
39 ultrasound as a diagnostic test in GCA is dependent not only on local expertise and 
41 experience in the technique itself, but also on the entire care pathway for patients with 
42 
43 suspected GCA including appropriate, timely referrals and clinical expertise such that the 
44 
45 results of the test can be interpreted appropriately. 
46 
47 As another example, follow up every 2-8 weeks for the first six months (less frequently 
48 
49 thereafter), may seem ambitious but this could be delivered via a shared care model in 
50 
51 collaboration with primary care, by which the patient and general practitioner receives the 
52 
53 information and support they need and has ready access to secondary care if need be. 
54 
55 Nonetheless it is also recognized that specific quality standards are necessary to drive 
56 




This guideline represents a framework upon which clinical practice should be based. 
However, as with any guideline, individual patient circumstances can have important 
influences on clinical decision-making, and clinicians should continue to work alongside 
patients to make shared decisions about care. Failure to adhere to this guideline should not 










3 Cost and cost-effectiveness implications for implementation 
4 
5 
6 A formal health economic evaluation was not conducted as part of the guideline 
7 development process. 
9 
10 Use of additional imaging tests could incur healthcare costs. This has to be set against the 
11 
12 advantages of accurate, timely diagnosis of GCA, in particular the potential cost savings of 
13 avoiding unnecessary treatment of patients without the disease. 
15 
16 A UK National Institute for Health and Care Excellence (NICE) technology appraisal has been 
17 
18 conducted with regard to tocilizumab therapy for GCA(113), which has the potential to 
19 significantly increase the direct costs of drug treatment of GCA. Both biologic and non- 
21 biologic therapies used alongside glucocorticoid treatment would incur additional costs due 
22 
23 to the requirements for regular blood monitoring. However, again this must be set against 
24 
25 the potential cost savings arising from reduction in cumulative glucocorticoid doses and 
26 
27 thereby a reduction in glucocorticoid-associated adverse events. On the basis of overall 
28 
29 cost-effectiveness data, approval was granted by NHS England and the Scottish Medicines 
30 Consortium for tocilizumab treatment for defined GCA patient groups; readers are directed 
32 to the appropriate guidance for a fuller explanation. 
33 
34 
35 Mechanism for auditing compliance with Guideline 
36 
37 Quality standards have been defined based on the fundamentals of good clinical care, as 
38 
39 outlined in the General Principles. Audit should be performed on an unbiased (e.g. 
40 
41 consecutive) sample of patients presenting to a clinic or service. A draft Audit Tool may be 
42 
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28 Table 1. A proposed list of clinical assessments that could be carried out at or near diagnosis 































History and examination Investigations 
 Height and weight 
 Features of giant cell arteritis relevant 
to prognosis: fever, sweats, or weight 
loss; ischaemic manifestations (jaw 
claudication, tongue claudication) 
 Signs and symptoms indicating 
involvement of extracranial arteries 
e.g. bruits, different blood pressures in 
the two arms, limb claudication 
 Ophthalmological evaluation for 
patients with transient or permanent 
visual loss or diplopia 
 History of comorbidities and 
medications that might predispose to 
glucocorticoid-related adverse effects: 
 Measures of activity of GCA: 
laboratory markers of inflammation 
(CRP for all patients, plus either ESR 
or plasma viscosity), and full blood 
count (platelet count may be 
elevated in GCA). 
 Consider serum protein 
electrophoresis and urine Bence- 
Jones protein/serum free light 
chains if ESR raised out of 
proportion to CRP 
 Baseline laboratory tests of major 
organ system function (plasma 
glucose, renal and liver function 
 




























23 *Screening tests for infection and osteoporosis to be considered in light of relevant local 
24 
25 and national guidelines. Abbreviations: CRP, C-reactive protein; ESR, erythrocyte 




31 Table 2. A typical glucocorticoid tapering schedule for giant cell arteritis. 
32 
33 
34 This is an example of a typical glucocorticoid taper schedule, based on that described in the 
35 
36 2010 BSR guidelines for GCA(114) and similar to the control arm of a recent GCA clinical 
37 trial(94). High-quality evidence comparing different glucocorticoid taper schedules in GCA is 
39 not available. Alternative approaches include, for example, reducing prednisolone by 
40 
41 10mg/week in patients who are in remission above 20mg daily, and/or reducing the dose 
42 
43 slower than stated here in patients who are on or below 5mg daily. In all cases taper 
44 
45 schedules should be individualised based on the patient. For relapse management, see 
46 














infection, hypertension, diabetes, 
osteoporosis, low-trauma fracture, 
dyslipidaemia, peptic ulcer, psychiatric 
adverse effects 
 Features that may suggest alternative 
diagnosis, e.g.: neurological deficits, 
very severe constitutional symptoms, 
or localised ear, nose and throat signs 
tests, calcium and alkaline 
phosphatase) 
 Screening tests for risk of serious 
infection* (may include urine 
dipstick, chest radiograph, tests for 
latent tuberculosis according to 
local or national protocol) 
 Screening tests for osteoporosis 
risk* (may include TSH, vitamin D, 
bone density test) (DXA) 
 
Daily prednisolone dose Example rate of 




prednisolone: initial dose 
Continue at same dose 
until GCA symptoms and 
Purpose: induction of 
clinical remission 
 





























25 Table 3. Examples of symptoms that may signify relapse of GCA during glucocorticoid taper 
26 
27 that require further evaluation and, if judged to be due to GCA relapse, escalation of 
28 
29 glucocorticoid treatment. 
30 
31 
This table outlines how new symptoms in GCA patients, in the absence of other risk factors 
33 or significant co-morbidities, may influence management decisions. New visual loss or 
34 
35 diplopia should be urgently evaluated by an ophthalmologist. Acute phase markers should 
36 
37 be measured and, if found to be elevated, may increase the clinical suspicion of GCA 
38 
39 relapse. At present, the only agents with any evidence for glucocorticoid-sparing in GCA are 
40 




















for patients with active 
GCA 
acute phase markers 
resolve 
 
In clinical remission, and 
above 20mg prednisolone 
Reduce daily dose by 
10mg every 2 weeks 
Aim to reach 20mg 
prednisolone once the 
patient has been in 
remission for 4-8 weeks. 
If symptoms suggestive of 
GCA relapse occur during 
taper, consult Table 3 
In clinical remission, 
above 10mg prednisolone 
but less than 20mg 
Reduce daily dose by 
2.5mg every 2-4 weeks 
In clinical remission, and 
on 10mg prednisolone or 
less 
Reduce daily dose by 1mg 
every 1-2 months 
 
Symptom Possible significance in a 
patient with GCA 
Action to consider if 
symptom is judged to be 
due to GCA relapse 
Return of headache 
symptoms 
Possible GCA relapse 
without ischaemic 
manifestations 
Return to previous higher 
prednisolone dose 
 




































32 Figure 1. A possible approach to using rapid-access vascular ultrasound to assist in clinical 



























Jaw or tongue 
claudication 
Possible GCA relapse with 
ischaemic manifestations 
Consider high-dose oral 
prednisolone (40-60mg) 
with or without 
glucocorticoid-sparing 
agent 
Weight loss, fever, night Possible GCA-related Investigate with vascular 
sweats, anaemia, inflammation of the aorta imaging (MRI, CT or FDG- 
persistent acute phase and/or its proximal PET-CT); consider 
response, new/recurrent branches increasing oral 
PMR symptoms, limb  prednisolone and/or 
claudication, abdominal  adding glucocorticoid- 
pain or back pain  sparing agent 
 














Biopsy positive Biopsy negative 









High (>50%) Medium 
(20-50%), 











































35 This figure illustrates a possible approach to using rapid-access vascular ultrasound, if 
36 
37 available, in suspected GCA. Estimation of probability of GCA is based on all information 
38 available (symptoms, signs, laboratory tests, and alternative non-GCA explanations for the 
40 clinical picture) and can be updated based on new information (clinical course, result of 
41 
42 temporal and axillary ultrasound and/or result of temporal artery biopsy). This assessment 
43 
44 is based on clinical judgement and should ideally be performed by an individual with 
45 
46 specialist expertise. Note that for a medium (20-50%) estimated probability of GCA, it may 
47 
48 be useful to perform an ultrasound prior to biopsy, in case the biopsy is negative. For a high 
49 clinical probability of GCA, a positive ultrasound alone may be sufficient, as illustrated here; 
51 however, in these cases it is still acceptable to perform biopsy in addition to ultrasound in 
52 
53 order to further increase diagnostic certainty. In the absence of clinical features of cranial 
54 
55 GCA, temporal artery biopsy can still be positive, but imaging of the extracranial large 
56 
57 vessels may be considered instead of, or in addition to, temporal artery biopsy. Recently 
58 
59 various clinical prediction rules have been proposed to assist clinicians in the estimation of 
60 










3 probability of GCA; the performance of a clinical prediction rule developed in another 
4 
5 setting should ideally be checked using local audit data prior to adopting into local clinical 
6 
7 practice. If rapid-access vascular ultrasound is not available, patients treated for suspected 
8 
9 GCA should all have a temporal artery biopsy. None of these tests should delay the 
10 











Anti-neutrophil cytoplasmic antibodies 
21 BSR British Society for Rheumatology 
22 
23 CI Confidence interval 
24 CRP C-reactive protein 
26 CT Computed tomography 
27 
28 CTA Computed tomography angiography 
29 
30 DB-RCT Double-blinded randomised controlled trial 
31 
32 ESR Erythrocyte sedimentation rate 
33 
34 FDG 18F-Fluorodeoxyglucose 
35 GCA Giant cell arteritis 
37 GP General practitioner 
38 




43 ISRCTN International Standard Randomised Controlled Trial Number Register 
44 
45 LR Likelihood ratio 
46 MRI Magnetic resonance imaging 
48 NSAIDS Non-steroidal anti-inflammatory drugs 
49 
50 PET Positron emission tomography 
51 








Quality In Prognosis Studies 
Quality of Evidence 
Randomised controlled trial 
Swedish Council on Technology Assessment in Health Care 





















Systematic literature review 
Tumor necrosis factor-alpha inhibitor 





Appendix B. List of critical outcome parameters, adapted from the PMR guidelines 




 Sight loss and other ischaemic complications 
18  Disease remission 
19 
20  Disease relapse 
21 
22  Duration of glucocorticoid therapy 
23  Discontinuation of glucocorticoid therapy 
25 
 Glucocorticoid side effects 
26 
27  Other therapy related side effects 
28 
29  Response to glucocorticoid therapy 
30  Cumulative glucocorticoid dose 
32 
 Inflammatory markers (i.e. ESR, CRP) 
34  Patients assessment of global wellbeing (VAS – Visual analogue score) 
35 
36  Severity (VAS) / duration (minutes) of morning stiffness 
37 
38  Lowest possible glucocorticoid dose (Prednisolone less than 5mg/day) 
39  Functional status ( HAQ or other measures) 
41  Quality of life (SF-36, EQ5D etc.) 
42 
43  Cardiovascular events (MI,strokes,PVD) 
44 
45  Mortality 
46  Hospitalization (due to disease, its complications, co-morbidity and/or treatment related 
48 complications) 
49  Impact on patients’ social environment 
51 
 Fatigue 
53  Imaging of shoulder/hip 
54 
55  Healthcare resource use (health economics) 
56 














3 Appendix C. List of questions structured in PICO format (Patients, Intervention, 
5 Comparator, Outcome) 
6 
7 
8 Diagnostic imaging PICOs: 
9 
10 
11 Should ultrasound (I) be used for the diagnosis of GCA (O) in patients with suspected GCA 




17 Investigation of sources of heterogeneity: 
18 
19 
(P): the target population may be defined by different criteria including new onset 
21 headache, polymyalgic syndrome and/or unexplained constitutional symptoms. 
22 
23 
24 (I): Duplex ultrasound of temporal and/or extracranial arteries with different ultrasound 
25 pathologies including the halo sign, compression sign, stenosis, occlusion. 
27 
28 (C): clinical diagnosis (without formal criteria), ACR classification criteria and temporal artery 
29 














44 Initial oral glucocorticoid dose 
45 
46 1. In GCA (P), what is the effect of oral glucocorticoids at doses <40 mg/day prednisone 
47 
48 equivalent) (I) on outcome (O) compared with doses between 40 and 60 mg/day 
49 
50 prednisone equivalent (C)? 
51 
52 2. In GCA (P), what is the effect of oral glucocorticoids at doses 40-60 mg/day 
53 
54 prednisone equivalent (I) on outcome (O) compared with doses >60 but ≤ 100 
55 
56 mg/day of prednisone equivalent (C)? 
57 
58 3. In GCA (P) what is the effect of oral glucocorticoids at doses of 0.5 mg/kg/day 
59 
60 prednisone equivalent (i) on outcome (O) compared with doses of 1 mg/kg/day (C)? 









3 4. In GCA (P), what is the effect of intravenous methylprednisolone pulse therapy 
4 
5 (>100mg and ≤1000mg per day over 3 consecutive day) plus oral glucocorticoids (I) 
6 
7 on outcome (O) compared with oral glucocorticoids alone (C)? 
8 
9 Glucocorticoid schedule 
10 
11 
12 5. In GCA (P), what is the effect of rapid taper of glucocorticoids (I) on outcome (O) 
13 compared with slow taper of glucocorticoids (C)? 
15 
16 Divided versus single dosage of oral glucocorticoids 
17 
18 6. In GCA (P), what is the effect of administration of oral glucocorticoid therapy at 
19 
20 divided doses (morning plus evening) (I) on outcome (O) compared with single dose 
21 
22 (morning only) (C)? 
23 
24 7. In GCA (P), what is the effect of administration of oral glucocorticoid therapy as 
25 
26 alternate day doses (I) on outcome (O) compared with single dose (C)? 
27 
28 Modified release glucocorticoid preparations 
29 
30 
31 8. In GCA (P), what is the effect of treatment with oral modified-release prednisolone 
32 (I) on outcome (O) compared with standard prednisolone at equivalent dose (C)? 
34 
35 Role of non-biologic disease modifying anti-rheumatic drugs 
36 
37 9. In GCA (P), what is the effect of glucocorticoids plus methotrexate (I) on outcome (O) 
38 
39 compared with glucocorticoids alone (C)? 
40 
41 10. In GCA (P), what is the effect of glucocorticoids plus non-biological disease modifying 
42 
43 anti-rheumatic drugs (non-methotrexate DMARDs) (I) on outcome (O) compared 
44 
45 with glucocorticoids alone (C)? 
46 
47 Role of biological disease modifying anti-rheumatic drugs 
48 
49 
50 11. In GCA (P), what is the effect of glucocorticoids plus biological agents (I) on outcome 
51 (O) compared with glucocorticoids alone (C)? 
53 
54 Role of aspirin and anticoagulants 
55 
56 12. In GCA (P), what is the effect of aspirin plus glucocorticoids (I) on outcome (O) 
57 
58 compared with glucocorticoids alone (C)? 
59 
60 










3 13. In GCA (P), what is the effect of (standard or low molecular weight) heparin plus 
4 
5 glucocorticoids (I) on outcome (O) compared with glucocorticoids alone (C)? 
6 
7 
14. In GCA (P), what is the effect of warfarin plus glucocorticoids (I) on outcome (O) 
9 compared with glucocorticoids alone (C)? 
10 
11 
12 15. In GCA (P), what is the effect of new oral anticoagulants (NOACs) plus glucocorticoids 
13 (I) on outcome (O) compared with glucocorticoids alone (C)? 
15 
16 Role of Statins 
17 
18 16. In GCA (P), what is the effect of statins plus glucocorticoids (I) on outcome (O) 
19 
20 compared with glucocorticoids alone (C)? 
21 
22 Role of non-pharmacological therapy 
23 
24 
25 17. In GCA (P), what is the effect of glucocorticoids plus exercise programme (I) on 









36 1. In GCA (P), what is the effect of older age at diagnosis (I) on outcome (O) compared 
37 
38 with younger age (C)? 
39 
40 2. In GCA (P), what is the effect of female sex (I) on outcome (O) compared with male 
41 
42 sex (C)? 
43 
44 3. In GCA (P), what is the effect of high levels of inflammatory markers, erythrocyte 
45 
46 sedimentation rate (ESR) and/or C-reactive protein (CRP), at diagnosis (I) on 
47 
48 outcome (O) compared with low levels of inflammatory markers (C)? 
49 
50 4. In GCA (P), what is the effect of more active/severe disease at diagnosis (I) on 
51 
52 outcome (O) compared with lower disease activity/severity (C)? 
53 
54 5. In GCA (P), what is the effect of rapid response to glucocorticoids (I) on outcome (O) 
55 
56 compared with delayed response (C)? 
57 
58 6. In GCA (P), what is the effect of positive TAB histology (I) on outcome (O) compared 
60 with negative TAB histology (C)? 











6 To avoid prematurely imposing cut-points and risking loss of important information, the 
7 group decided not to define cut-points for the following prognostic factor categories at this 
9 stage of the SLR: “rapid/slow taper of glucocorticoid therapy” “older/younger age”, 
10 
11 “high/low levels of inflammatory markers”, “more/less active/severe disease”, 
12 




17 Appendix D. Search strategies (shown for MEDLNE only, similar strategies were 





24 Search strategy for diagnostic studies 
25 
26 Key words for (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
27 
28 MEDLINE(R) 1946 to Present; Ovid MEDLINE(R) Daily Update): 
29 





35 1. exp Giant Cell Arteritis/ 
36 
37 2. (temporal ADJ2 arteritis).mp. 
38 
39 3. (giant ADJ2 cell ADJ2 arteritis).mp. 
40 
41 
42 4. Horton.mp 
43 
44 5. GCA.mp 
45 
46 6. Exp Aortitis/ 
47 
48 
49 7. large vessel vasculitis.mp 
50 
51 8. large vessel arteritis.mp 
52 
53 9. polymyalgia arteritica.mp. 
54 
55 
56 10. single organ arteritis.mp 
57 
58 11. single organ vasculitis.mp 
59 
60 






3 12. OR/1-11 
4 
5 
6 13. sensitiv*.mp 
7 
8 14. specific*.mp 
9 
10 15. reliab*.mp 
11 
12 
13 16. positiv*.mp 
14 
15 17. negativ*.mp 
16 
17 18. diagnos*.mp 
18 
19 
20 19. detect*.mp 
21 
22 20. di.fs 
23 
24 21. predict*.mp 
25 
26 
27 22. accura*.mp 
28 
29 23. (observer adj variation*).mp 
30 
31 24. (roc adj curve*).mp 
32 
33 
34 25. (likelihood adj3 ratio*).mp 
35 
36 26. likelihood function/ 
37 
38 27. OR/13-26 
39 
40 
41 28. exp Ultrasonography/ 
42 
43 29. ultrasound.mp 
44 
45 30. ultrasonograph*.mp. 
46 
47 
48 31. sonograp*.mp. 
49 
50 32. (Colour ADJ2 Doppler).mp 
51 
52 33. OR/28-32 
53 
54 
55 34. 12 AND 27 AND 33 
56 
57 35. Exp Magnetic Resonance Imaging/ 
58 
59 36. MR imag*.mp. 
60 







3 37. MRI.mp 
4 
5 
6 38. magnetic resonance imag*.mp 
7 
8 39. OR/35-38 
9 
10 40. 12 AND 27 AND 39 
11 
12 
13 41. exp Positron Emission Tomography/ 
14 
15 42. Exp tomography, emission-computed/ 
16 
17 43. (Positron ADJ2 Emission ADJ2 Tomography).mp 
18 
19 
20 44. Pet.mp 
21 
22 45. pet*.mp 
23 
24 46. petscan*.mp 
25 
26 
27 47. emission.mp AND tomograph.mp 
28 
29 48. Tomographs.mp 
30 
31 49. tomographic*.mp 
32 
33 
34 50. tomography.mpt 
35 
36 51. tomographies.mp 
37 
38 52. OR/41-51 
39 
40 
41 53. 12 AND 27 AND 52 
42 





48 Limit: English language 
49 





55 Key words for (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
56 MEDLINE(R) 1946 to Present; Ovid MEDLINE(R) Daily Update): 
58 
59 Exp, explode; *, truncation; /, Mesh term; mp, keyword; ADJ, adjacent 
60 










6 1. exp Giant Cell Arteritis/ 
7 
8 2. (temporal ADJ2 arteritis).mp. 
9 
10 3. (giant ADJ2 cell ADJ2 arteritis).mp. 
11 
12 
13 4. Horton.mp 
14 
15 5. GCA.mp 
16 
17 6. Exp Aortitis/ 
18 
19 
20 7. large vessel vasculitis.mp 
21 
22 8. large vessel arteritis.mp 
23 
24 9. polymyalgia arteritica.mp. 
25 
26 
27 10. single organ arteritis.mp 
28 
29 11. single organ vasculitis.mp 
30 
31 12. OR/1-11 
32 
33 
34 13. Exp Clinical Trial/ 
35 
36 14. randomized controlled trial.pt. 
37 
38 15. controlled clinical trial.pt 
39 
40 
41 16. random*.mp 
42 
43 17. placebo.mp 
44 
45 18. trial.mp 
46 
47 
48 19. OR/13-18 
49 
50 20. 12 AND 19 
51 






















3 Key words for (Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
4 
5 MEDLINE(R) 1946 to Present; Ovid MEDLINE(R) Daily Update): 
6 
7 




12 1. exp Giant Cell Arteritis/ 
13 
14 
2. (temporal ADJ2 arteritis).mp. 
16 
17 3. (giant ADJ2 cell ADJ2 arteritis).mp. 
18 





24 6. Exp Aortitis/ 
25 
26 7. large vessel vasculitis.mp 
27 
28 
8. large vessel arteritis.mp 
30 
31 9. polymyalgia arteritica.mp. 
32 
33 10. single organ arteritis.mp 
34 
35 
11. single organ vasculitis.mp 
37 
38 12. OR/1-11 
39 
40 13. Prognos*.mp 
41 
42 14. Predict*.mp 
44 
45 15. Course*.mp 
46 
47 16. follow-up stud*.mp 
48 
49 17. case-control stud*.mp 
51 
52 18. cohort stud*.mp 
53 
54 19. comparative stud*.mp 
55 
56 20. longitudinal stud*.mp 
58 
59 21. program evaluation.mp 
60 






3 22. prospective stud*.mp 
4 
5 
6 23. treatment outcome.mp 
7 
8 24. risk factor*.mp 
9 
10 25. OR/13-24 
11 
12 
13 26. 12 AND 25 
14 





20 Appendix E. Likelihood ratios for various imaging tests for GCA 
21 These likelihood ratios (LRs) are calculated from the diagnostic studies reported in the main text; LRs 
22 
23 are another way of presenting sensitivity and specificity (diagnostic accuracy) data. Random-effects 
24 
25 meta-analysis was used to generate pooled LRs. A LR of 1.0 indicates a useless test; a LR of 2.0 would 
26 double the odds that the disease is present, whereas a LR of 0.5 would halve the odds that the disease 
27 
28 is present. For comparison, a positive temporal artery biopsy would have an estimated LR of 98, and 
29 
30 a negative biopsy would have a LR of 0.61, in relation to clinical diagnosis of GCA (data extracted from 
31 TABUL study (19); similar likelihood ratios for biopsy vs clinical diagnosis were reported in another 
32 
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5 3.7 (2.4 – 5.9) 0.08 (0.045 – 0.15) 
 
























































This is an example of a care pathway for suspected GCA that was implemented at one 
53 hospital, Southend University Hospital NHS Foundation Trust, UK. This care pathway, which 
54 
55 was called the “fast track pathway”, was awarded a 2016 BSR Case Study for Outstanding 
56 














1 3.8 (1.7 – 8.5) 0.54 (0.30 – 0.98) 
CT angiography Clinical 
diagnosis of 
GCA 
1 3.3 (0.94 – 12) 0.34 (0.14 – 0.85) 
 










3 Other hospitals have developed different care pathways depending on their local 
4 





10 Appendix G. Research agenda 
11 
12 
13 The group agreed that future clinical trials in GCA should be well-designed and properly 
14 powered. A core outcome set for future GCA clinical trials would ensure that outcomes of 
16 importance to all stakeholder groups are included in all GCA trials; as well as facilitating 
17 
18 regulatory approvals this would also be beneficial for future evidence synthesis. A recent 
19 




24 Specific research questions: 
25 1. How could we improve methods for diagnosis of GCA (including imaging, biomarkers 
27 and clinical algorithms, as well as organizational changes to care pathways)? Are clinical 
28 
29 prediction scores that estimate the probability of GCA using clinical and laboratory features 
30 
31 useful in the setting of suspected GCA? 
32 
33 2. What outcome measures, including patient-reported outcomes, response-, remission- 
34 
35 and relapse-criteria, imaging outcomes, and composite outcome measure scores, should be 
36 used in GCA clinical trials and in clinical practice? 
38 3. What is the efficacy and safety of different routes of glucocorticoid administration (oral, 
39 
40 intramuscular, intraarticular), different initial glucocorticoid doses, different glucocorticoid 
41 
42 tapering regimens, and different glucocorticoid flare doses? In particular, does high-dose 
43 
44 oral prednisolone differ in efficacy and safety from intravenous methylprednisolone? 
45 
46 4. What is the efficacy and safety of additional therapies, both non-TNF biologic and 
47 other novel therapies, and oral DMARDs such as methotrexate, leflunomide, azathioprine 
49 and mycophenolate? What is the optimal strategy to use additional therapies in GCA: 
50 
51 monotherapy versus combination therapy, early versus late introduction and (particularly 
52 
53 for biologics) use of them with or without glucocorticoids? 
54 
55 5. What can we learn from post-marketing studies of tocilizumab, including registries 
56 















3 6. What is the minimal/optimal duration of glucocorticoid therapy? In patients who 
4 
5 need additional therapy (either non-biologic DMARD, or biologic) how long should this 
6 
7 additional therapy be given and how should we manage patients who need to stop 
8 
9 additional therapies? 
10 
11 7. Is aspirin beneficial for patients with GCA, in those patients for whom aspirin is not 
12 already indicated for other reasons? 
14 8. What is the optimal strategy for shared primary and specialty care? How can 
15 
16 patients better be involved in treatment decisions? Can we develop decision aid tools to 
17 
18 help doctors and patients make more informed, shared decisions about management 
19 
20 options in GCA? What should self-management mean in GCA? 
21 
22 9. What is the value of tight control (or “treat to target”) versus conventional 
23 management strategies in GCA? 
25 10. How should patients with long-standing GCA and long-term, low-dose glucocorticoid 
26 
27 therapy be managed? 
28 
29 11. What are the health economic implications (cost-utility, cost-effectiveness) of 
30 
31 different ways of diagnosing and managing GCA? 
32 
33 12. What is the value of non-pharmacological therapies in GCA? This includes exercise, 
34 physiotherapy, diet, and nutritional supplements including fish oils. 
36 13. What imaging tests (including, but not limited to, ultrasound) may be useful for the 
37 
38 diagnosis and monitoring of GCA, including identification of overlap with other diseases (e.g. 
39 
40 PMR, large vessel vasculitis or inflammatory arthritis)? 
41 
42 14. Which soluble and tissue biomarkers may be useful in the diagnosis and monitoring 
43 
44 of GCA? 
45 15. What factors are prognostic in GCA? Can we define prognostically-relevant 
47 subgroups of GCA patients, and can we reach a better understanding of the mechanisms 
48 
49 underlying these prognostic factors? Should prognostic factors guide stratified care in GCA 
50 
51 (treatment strategies selected on the basis of the patient’s prognostic subgroup)? 
52 
53 16. Since drugs targeted to IL-6 pathways (eg tocilizumab) can suppress levels of CRP 
54 
55 and ESR, how should we monitor disease activity in GCA patients receiving treatment with 















3 17. What is the morbidity and mortality of GCA patients (with a particular focus on 
4 
5 cardiovascular risk) in long-term observational studies? 
6 
7 18. What is the aetiopathogenesis of GCA? Which targeted therapies could be 
8 
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4 British Society for Rheumatology Audit Tool for Giant Cell Arteritis 
5 
6 
7 Aim: This audit tool has been designed to help clinicians audit the investigation and management of 
8 
9 giant cell arteritis (GCA) according to the 2019 BSR guidelines. It should be performed on an unbiased 






 Following first medical contact in which GCA is suspected, patients should be reviewed by an 
16 
17 appropriate specialist within 3 working days. 
18 
19  Patients in whom GCA is strongly suspected should be treated with high-dose 
20 glucocorticoids on the same calendar day (either at least 40mg prednisolone equivalent, or 
21 intravenous methylprednisolone). 
23 
 Before or immediately after commencing high-dose glucocorticoids for suspected GCA, 
25 patients should have had blood sent to the laboratory for full blood count, CRP, and ESR (or 
26 plasma viscosity if ESR unavailable). 
27 
28 
 Patients commenced on high-dose glucocorticoids for suspected GCA should undergo an 
29 
30 additional confirmatory test, such as temporal artery biopsy or vascular imaging (e.g. 
31 vascular ultrasound, 3T MRI of cranial artery, or CT/PET). 
32 
33  Patients with GCA-related visual symptoms (transient/permanent visual loss or diplopia) 
34 should be reviewed on the same calendar day by an ophthalmologist. 
35 
36 
 Patients commencing high-dose glucocorticoids should have a random venous blood glucose 
38 or HbA1c or capillary blood glucose (CBG) checked within the first 2 weeks and any 
39 hyperglycaemia be managed appropriately. 
40 
41  Patients commencing high-dose glucocorticoids for suspected GCA should have 
42 
43 consideration of appropriate bone protection according to the applicable local or national 
44 guidelines (e.g. calcium and vitamin D, with oral bisphosphonate unless contra-indicated). 
45 
46  Patients with confirmed GCA should be offered written information about their condition 
47 (for example, the Versus Arthritis leaflet on GCA, or locally-agreed equivalent), including 
48 
49 advice on sources of further information and support in addition to medical advice from 
50 their care providers. Patients should be advised which matters could be dealt with by their 
51 GP, and how to contact their specialist if they need to. 
52 
53 
 Patients with confirmed GCA should have documentation of a discussion about what 
54 
55 symptoms may signal GCA relapse, and what action they should take in the event of a 
56 possible relapse, including the appropriate level of urgency for symptoms that may indicate 
57 threatened visual loss. 
58 














4 For patients with suspected GCA: 




9 0 - 1 ☐ 2-3 ☐ 4-5☐ >5 ☐ 
10 
11 2. What was the interval between first strong suspicion of GCA and first initiation of high- 
12 dose glucocorticoid therapy? 
13 
14 
<24 hrs ☐ 24-48 hours ☐ >48 hours ☐ not strong suspicion☐ 
16 
3. Were FBC, CRP and either ESR or plasma viscosity requested in the 3 weeks prior to, or 
18 immediately after initiation of high-dose glucocorticoid therapy? 
19 
20 yes ☐ no ☐ 
21 
22 4. What was the initial daily dose of prednis(ol)one therapy for GCA? 
23 
24 <40mg ☐ 40-60mg ☐ >60mg ☐ iv therapy ☐ never treated☐ 
25 
26 5. What additional confirmatory test was performed? 
27 
28 ultrasound ☐ biopsy ☐ other appropriate imaging test ☐ no test ☐ 
29 
30 




35 Yes ☐ No ☐ 
36 Ophthalmological diagnosis was (Please circle) Anterior ischaemic optic neuropathy, double 
37 vision, central retinal artery occlusion, branch retinal artery occlusion, choroidal ischaemia, 
38 other 
39    
40 Additional items, for patients with confirmed GCA: 
42 
43 7. Within the first 2 weeks of treatment which of these are documented? 
44 
45 random glucose or HbA1c ☐ blood pressure ☐ 
46 
47 
48 vitamin D and calcium prescribed ☐ appropriate bone protection therapy ☐ 
49 
50 8. Is there documentation of provision of written information about the condition, including 
51 information about sources of further information and support? 
53 
54 Yes ☐ No ☐ 
55 9. Is there documentation of a discussion with the patient/carers about symptoms to watch 
57 out for and what to do if they experience symptoms suggesting GCA relapse? 
58 
59 Yes ☐ No ☐ 
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